{"filter":{"intervention":"drug_therapy"},"n_projects":126,"projects":[{"accession":"PRJEB37731","age_categories":{"adolescent":1,"adult":2824},"countries":{"DK":2804,"SE":21},"first_public_year":"2020","gbp_per_sample_median":0.23,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":false,"health_conditions":{"allergy_or_atopy":637,"autoimmune_inflammatory":23,"cardiometabolic_other":8,"healthy_control":1877,"neurological_psychiatric":54,"other_infection":210,"ulcerative_colitis":16},"intervention_design":"non_randomized_controlled","intervention_detail":"Hormonal contraceptives: combined oral contraceptive or levonorgestrel IUS vs non-hormonal methods","interventions":["drug_therapy"],"n_samples":2825,"papers":[{"doi":"10.1128/msphere.00448-20","pmcid":"PMC7677004","pmid":"33208514","title":"Assessment of In Vitro and In Silico Protocols for Sequence-Based Characterization of the Human Vaginal Microbiome."},{"doi":"10.3389/fcimb.2021.625229","pmcid":"PMC8018275","pmid":"33816334","title":"Dysbiosis of the Human Oral Microbiome During the Menstrual Cycle and Vulnerability to the External Exposures of Smoking and Dietary Sugar."},{"doi":"10.1093/humrep/deac094","pmcid":"PMC9247429","pmid":"35553675","title":"The healthy female microbiome across body sites: effect of hormonal contraceptives and the menstrual cycle."},{"doi":"10.3389/fcimb.2024.1324794","pmcid":"PMC11249552","pmid":"39015337","title":"Investigations of microbiota composition and neuroactive pathways in association with symptoms of stress and depression in a cohort of healthy women."},{"doi":"10.1186/s40168-024-01870-5","pmcid":"PMC11331738","pmid":"39160615","title":"Defining Vaginal Community Dynamics: daily microbiome transitions, the role of menstruation, bacteriophages, and bacterial genes."}],"sample_intervention_arms":{},"sex":{"female":2825},"title":"Effects of the menstrual cycle and hormonal contraceptives on the human microbiome","trial_population_condition":"healthy_control","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB37731","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB37731_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB37731.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB37731.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB37731.csv.gz"}},{"accession":"PRJNA643353","age_categories":{"adult":1156,"elderly":36},"countries":{"CN":1192},"first_public_year":"2021","gbp_per_sample_median":10.73,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"type2_diabetes":1192},"intervention_design":"randomized_controlled_trial","intervention_detail":"Berberine and/or probiotics vs placebo, with gentamycin run-in pretreatment","interventions":["antibiotic","drug_therapy","probiotic"],"n_samples":1192,"papers":[{"doi":"10.1038/s41467-020-18414-8","pmcid":"PMC7538905","pmid":"33024120","title":"Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)."},{"doi":"10.1080/19490976.2021.2003176","pmcid":"PMC8726654","pmid":"34923903","title":"Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study."},{"doi":"10.1038/s41564-021-00920-0","pmcid":"PMC8318886","pmid":"34226711","title":"Probiotics impact the antibiotic resistance gene reservoir along the human GI tract in a person-specific and antibiotic-dependent manner."},{"doi":"10.1002/imt2.179","pmcid":"PMC11170963","pmid":"38882498","title":"Deciphering unique and shared interactions between the human gut microbiota and oral antidiabetic drugs."},{"doi":"10.1016/j.heliyon.2024.e37986","pmcid":"PMC11438002","pmid":"39347390","title":"Clinical significance of the genetically variable landscape of the gut microbiome in patients with gestational diabetes mellitus patients."}],"sample_intervention_arms":{"antibiotic":403,"drug_therapy":85,"no_intervention":405,"other_intervention":104,"placebo":97,"probiotic":98},"sex":{"female":146,"male":216},"title":"The gut microbiome related effect of Berberine and probiotics in treating Type 2 Diabetes","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA643353","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA643353_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA643353.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA643353.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA643353.csv.gz"}},{"accession":"PRJNA1139229","age_categories":{"unknown":723},"countries":{"HK":723},"first_public_year":"2024","gbp_per_sample_median":7.72,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"ibs":723},"intervention_design":"randomized_controlled_trial","intervention_detail":"JCM-16021 Chinese herbal formula vs placebo for IBS-D","interventions":["drug_therapy"],"n_samples":723,"papers":[{"doi":"10.1016/j.phymed.2025.157040","pmcid":null,"pmid":"40639240","title":"Butyrate-producing commensal bacteria mediates the efficacy of herbal medicine JCM-16021 on abdominal pain in diarrhea-predominant irritable bowel syndrome: a randomized clinical trial."}],"sample_intervention_arms":{},"sex":{},"title":"JCM-16021 in diarrhea-predominant irritable bowel syndrome: efficacy and gut microbiota interactions in a double-blinded randomized placebo-controlled trial","trial_population_condition":"ibs","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1139229","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1139229_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1139229.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1139229.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1139229.csv.gz"}},{"accession":"PRJNA797994","age_categories":{"adolescent":51,"adult":400,"child":174,"elderly":25},"countries":{"MY":650},"first_public_year":"2022","gbp_per_sample_median":3.01,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":true,"health_conditions":{"healthy_control":352,"other_infection":298},"intervention_design":"single_arm_before_after","intervention_detail":"Albendazole anthelmintic treatment (deworming), longitudinal pre/post sampling","interventions":["drug_therapy"],"n_samples":650,"papers":[{"doi":"10.1016/j.celrep.2022.111725","pmcid":"PMC9790084","pmid":"36450245","title":"Clostridia isolated from helminth-colonized humans promote the life cycle of Trichuris species."},{"doi":"10.1186/s40168-022-01385-x","pmcid":"PMC9727879","pmid":"36476263","title":"Gut microbiome of helminth-infected indigenous Malaysians is context dependent."},{"doi":"10.1038/s41467-025-61687-0","pmcid":"PMC12246136","pmid":"40640199","title":"Global diversity of soil-transmitted helminths reveals population-biased genetic variation that impacts diagnostic targets."},{"doi":"10.1038/s41467-026-71521-w","pmcid":"PMC13079874","pmid":"41980943","title":"Comprehensive benchmarking of metagenomic binning tools reveals key factors for improved genome recovery."}],"sample_intervention_arms":{"drug_therapy":243,"no_intervention":407},"sex":{"female":387,"male":263},"title":"Gut Microbiome of Helminth Infected Indigenous Malaysians Is Context Dependent","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA797994","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA797994_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA797994.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA797994.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA797994.csv.gz"}},{"accession":"PRJNA804384","age_categories":{"adolescent":8,"adult":386,"elderly":38},"countries":{},"first_public_year":"2022","gbp_per_sample_median":3.48,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"crohns_disease":312,"ulcerative_colitis":120},"intervention_design":"single_arm_before_after","intervention_detail":"Biological therapy (one of four agents) for IBD, pre/post samples","interventions":["drug_therapy"],"n_samples":432,"papers":[{"doi":"10.1093/ecco-jcc/jjad061","pmcid":"PMC10588789","pmid":"37052201","title":"Community Types of the Human Gut Virome are Associated with Endoscopic Outcome in Ulcerative Colitis."}],"sample_intervention_arms":{"drug_therapy":432},"sex":{"female":255,"male":177},"title":"Inflammatory bowel disease patients undergoing biological therapy","trial_population_condition":"ibd_unspecified","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA804384","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA804384_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA804384.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA804384.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA804384.csv.gz"}},{"accession":"PRJNA1249224","age_categories":{"adult":408},"countries":{"CI":408},"first_public_year":"2026","gbp_per_sample_median":11.06,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"gi_infection_or_diarrhoea":408},"intervention_design":"randomized_controlled_trial","intervention_detail":"Albendazole vs ivermectin-albendazole vs moxidectin-albendazole, RCT phase 3","interventions":["drug_therapy"],"n_samples":408,"papers":[{"doi":"10.1038/s41522-026-01018-3","pmcid":"PMC13503709","pmid":"42209510","title":"Combined high-quality metagenomics reveals off-target effects of albendazole, ivermectin-albendazole and moxidectin-albendazole on the human gut bacteria."},{"doi":"10.1101/2025.06.27.660518","pmcid":null,"pmid":null,"title":"Hybrid-metagenomics reveal off-target effects of albendazole, ivermectin-albendazole and moxidectin-albendazole on the human gut bacteria"}],"sample_intervention_arms":{"drug_therapy":1,"no_intervention":407},"sex":{},"title":"Metagenomic Illumina and Nanopore sequencing data of MAC study cohort","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1249224","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1249224_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1249224.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1249224.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1249224.csv.gz"}},{"accession":"SRP057027","age_categories":{"child":369},"countries":{},"first_public_year":"2015","gbp_per_sample_median":2.08,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":false,"health_conditions":{"crohns_disease":351,"healthy_control":18},"intervention_design":"none","intervention_detail":"","interventions":[],"n_samples":369,"papers":[{"doi":"10.1126/scitranslmed.aah6888","pmcid":"PMC5808452","pmid":"29141885","title":"A role for bacterial urease in gut dysbiosis and Crohn's disease."},{"doi":"10.1038/s41540-018-0063-2","pmcid":"PMC6068170","pmid":"30083388","title":"From metagenomic data to personalized in silico microbiotas: predicting dietary supplements for Crohn's disease."},{"doi":"10.1038/s41592-018-0182-0","pmcid":"PMC6289653","pmid":"30420687","title":"Quantifying and comparing bacterial growth dynamics in multiple metagenomic samples."},{"doi":"10.1038/s41579-019-0213-6","pmcid":"PMC6759048","pmid":"31249397","title":"Microbial genes and pathways in inflammatory bowel disease."},{"doi":"10.1186/s40168-019-0722-6","pmcid":"PMC6670193","pmid":"31370880","title":"Clustering co-abundant genes identifies components of the gut microbiome that are reproducibly associated with colorectal cancer and inflammatory bowel disease."}],"sample_intervention_arms":{"diet_intervention":143,"drug_therapy":200},"sex":{},"title":"Inflammation, Antibiotics, and Diet as Concurrent Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease","trial_population_condition":"crohns_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/SRP057027","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/SRP057027_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/SRP057027.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/SRP057027.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/SRP057027.csv.gz"}},{"accession":"PRJNA589866","age_categories":{"adult":135,"elderly":214},"countries":{"BG":107,"HU":32,"PL":36,"RO":87,"RS":81,"US":6},"first_public_year":"2020","gbp_per_sample_median":7.45,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{},"intervention_design":"randomized_controlled_trial","intervention_detail":"Ribaxamase (oral beta-lactamase) vs placebo with IV ceftriaxone","interventions":["antibiotic","drug_therapy"],"n_samples":349,"papers":[{"doi":"10.2147/idr.s260258","pmcid":"PMC7383106","pmid":"32801790","title":"Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone."}],"sample_intervention_arms":{"drug_therapy":129,"no_intervention":119,"placebo":101},"sex":{"female":139,"male":207},"title":"human gut metagenome Metagenome","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA589866","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA589866_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA589866.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA589866.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA589866.csv.gz"}},{"accession":"PRJNA1177516","age_categories":{"adult":345},"countries":{"US":345},"first_public_year":"2025","gbp_per_sample_median":7.56,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"liver_disease":30,"other_disease":315},"intervention_design":"single_arm_before_after","intervention_detail":"CFTR modulator elexacaftor/tezacaftor/ivacaftor (ETI), before/1mo/6mo after","interventions":["drug_therapy"],"n_samples":345,"papers":[{"doi":"10.1016/j.jcf.2025.05.006","pmcid":"PMC12393131","pmid":"40483244","title":"Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: Findings from the promise study"}],"sample_intervention_arms":{"drug_therapy":345},"sex":{},"title":"Changes in Fecal Microbiota in Adults with Cystic Fibrosis with 6 Months of CFTR Modulator Therapy Elexacaftor/Tezacaftor/Ivacaftor (ETI)","trial_population_condition":"other_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1177516","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1177516_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1177516.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1177516.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1177516.csv.gz"}},{"accession":"PRJEB95138","age_categories":{"adult":280},"countries":{"DK":280},"first_public_year":"2025","gbp_per_sample_median":6.12,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"healthy_control":280},"intervention_design":"randomized_controlled_trial","intervention_detail":"Oral prednisolone or IM methylprednisolone acetate vs saline, 7 days","interventions":["drug_therapy"],"n_samples":280,"papers":[{"doi":"10.1016/j.xcrm.2025.102426","pmcid":"PMC12711672","pmid":"41218604","title":"Glucocorticoid-induced changes of the gut microbiota and metabolic markers in healthy young men: Outcome of a randomized controlled trial."}],"sample_intervention_arms":{"no_intervention":56},"sex":{"male":280},"title":"Glucocorticoid-induced changes of the gut microbiota","trial_population_condition":"healthy_control","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB95138","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB95138_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB95138.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB95138.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB95138.csv.gz"}},{"accession":"PRJEB76817","age_categories":{"adult":261,"elderly":10},"countries":{"ES":271},"first_public_year":"2024","gbp_per_sample_median":6.72,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_infection":271},"intervention_design":"randomized_controlled_trial","intervention_detail":"Lamivudine/abacavir plus dolutegravir vs ritonavir-boosted darunavir (ART)","interventions":["drug_therapy"],"n_samples":271,"papers":[{"doi":"10.1038/s41467-026-69846-7","pmcid":"PMC12960958","pmid":"41781390","title":"Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial."}],"sample_intervention_arms":{"drug_therapy":263},"sex":{"female":34,"male":229},"title":"WMGS data from two-year, two-arm, randomized clinical trial comparing first-line antiretroviral therapy including dolutegravir vs. ritonavir-boosted darunavir in subjects with very advanced HIV-1 late presentation.","trial_population_condition":"other_infection","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB76817","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB76817_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB76817.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB76817.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB76817.csv.gz"}},{"accession":"PRJDB28938","age_categories":{"unknown":263},"countries":{},"first_public_year":"2026","gbp_per_sample_median":8.86,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":false,"health_conditions":{"healthy_control":131,"liver_disease":132},"intervention_design":"single_arm_before_after","intervention_detail":"UDCA treatment in treatment-naive PBC patients, samples before and after","interventions":["drug_therapy"],"n_samples":263,"papers":[{"doi":"10.1016/j.medj.2024.08.003","pmcid":null,"pmid":"39305900","title":"Gut microbiome pattern impacts treatment response in primary biliary cholangitis"}],"sample_intervention_arms":{},"sex":{},"title":"Multi-omics reveal host-microbiota interactions in primary biliary cholangitis (PRJCA018532)","trial_population_condition":"liver_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJDB28938","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJDB28938_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJDB28938.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJDB28938.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJDB28938.csv.gz"}},{"accession":"PRJEB94043","age_categories":{"adult":255},"countries":{"IT":255},"first_public_year":"2025","gbp_per_sample_median":11.92,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":255},"intervention_design":"randomized_controlled_trial","intervention_detail":"Donor FMT vs placebo FMT plus pembrolizumab and axitinib","interventions":["drug_therapy","fmt"],"n_samples":255,"papers":[{"doi":"10.1038/s41591-025-04189-2","pmcid":"PMC13099650","pmid":"41606119","title":"Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial."}],"sample_intervention_arms":{},"sex":{},"title":"Clinical trial (TACITO) for the evaluation of the efficacy of targeted of fecal microbiota transplantation (FMT) in improving response rates to immune checkpoint inhibitors (ICIs) in subjects with treatment-naïve metastatic renal cell carcinoma.","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB94043","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB94043_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB94043.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB94043.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB94043.csv.gz"}},{"accession":"PRJNA1169175","age_categories":{"adult":255},"countries":{"US":255},"first_public_year":"2024","gbp_per_sample_median":7.51,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"colorectal_cancer":255},"intervention_design":"single_arm_before_after","intervention_detail":"Oral fluoropyrimidine (5-FU) chemotherapy in CRC patients; mouse/ex vivo FMT & bacterial colonization","interventions":["drug_therapy"],"n_samples":255,"papers":[{"doi":"10.1126/scitranslmed.adq8870","pmcid":"PMC12087798","pmid":"40238917","title":"Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity."}],"sample_intervention_arms":{},"sex":{},"title":"Expansion of a bacterial operon during cancer treatment ameliorates drug toxicity","trial_population_condition":"colorectal_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1169175","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1169175_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1169175.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1169175.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1169175.csv.gz"}},{"accession":"PRJNA436359","age_categories":{"child":241},"countries":{"US":241},"first_public_year":"2024","gbp_per_sample_median":1.12,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"ulcerative_colitis":241},"intervention_design":"observational_with_procedure","intervention_detail":"Conventional UC treatments (e.g. 5-ASA, corticosteroids) compared pre/post","interventions":["drug_therapy"],"n_samples":241,"papers":[{"doi":"10.1016/j.chom.2018.09.009","pmcid":"PMC6277984","pmid":"30308161","title":"Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course."},{"doi":"10.1038/s41467-018-07841-3","pmcid":"PMC6318335","pmid":"30604764","title":"Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response."},{"doi":"10.1038/s41564-022-01224-7","pmcid":"PMC9728153","pmid":"36138166","title":"Inflammation-associated nitrate facilitates ectopic colonization of oral bacterium Veillonella parvula in the intestine."},{"doi":"10.1002/ueg2.12485","pmcid":"PMC10859715","pmid":"38041519","title":"Gut microbiota signatures in inflammatory bowel disease."},{"doi":"10.1016/j.chom.2023.12.013","pmcid":"PMC10923022","pmid":"38215740","title":"Linking microbial genes to plasma and stool metabolites uncovers host-microbial interactions underlying ulcerative colitis disease course."}],"sample_intervention_arms":{},"sex":{},"title":"Gut microbial factors implicated in disease progression and treatment response in pediatric ulcerative colitis","trial_population_condition":"ulcerative_colitis","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA436359","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA436359_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA436359.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA436359.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA436359.csv.gz"}},{"accession":"PRJEB70966","age_categories":{"adult":232},"countries":{"NL":232},"first_public_year":"2024","gbp_per_sample_median":3.96,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":232},"intervention_design":"observational_with_procedure","intervention_detail":"Immune checkpoint blockade (anti-PD-1) therapy for advanced melanoma","interventions":["drug_therapy"],"n_samples":232,"papers":[{"doi":"10.1038/s41591-024-02803-3","pmcid":"PMC10957474","pmid":"38365950","title":"Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma."},{"doi":"10.1016/j.chom.2024.10.006","pmcid":"PMC11629153","pmid":"39481388","title":"Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients."}],"sample_intervention_arms":{},"sex":{},"title":"Longitudinal gut microbiome changes in immune checkpoint blockade in advanced melanoma","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB70966","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB70966_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB70966.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB70966.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB70966.csv.gz"}},{"accession":"PRJEB62817","age_categories":{"adult":226},"countries":{"LV":226},"first_public_year":"2023","gbp_per_sample_median":6.74,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"type2_diabetes":226},"intervention_design":"single_arm_before_after","intervention_detail":"Metformin monotherapy in newly diagnosed T2D, sampled before/after","interventions":["drug_therapy"],"n_samples":226,"papers":[{"doi":"10.1080/19490976.2024.2361491","pmcid":"PMC11178274","pmid":"38868903","title":"Gut microbiome encoded purine and amino acid pathways present prospective biomarkers for predicting metformin therapy efficacy in newly diagnosed T2D patients."}],"sample_intervention_arms":{},"sex":{},"title":"Gut microbiome encoded purine and amino acid pathways present prospective biomarkers for predicting metformin therapy efficacy in newly diagnosed T2D patients","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB62817","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB62817_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB62817.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB62817.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB62817.csv.gz"}},{"accession":"PRJEB22863","age_categories":{"adult":125,"elderly":94},"countries":{"FR":219},"first_public_year":"2017","gbp_per_sample_median":2.99,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"other_cancer":219},"intervention_design":"observational_with_procedure","intervention_detail":"Anti-PD-1 therapy; FMT and A. muciniphila supplementation in mouse models","interventions":["drug_therapy","fmt","probiotic"],"n_samples":219,"papers":[{"doi":"10.1126/science.aan3706","pmcid":null,"pmid":"29097494","title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors."},{"doi":"10.3389/fonc.2022.837525","pmcid":"PMC9069064","pmid":"35530307","title":"Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients."},{"doi":"10.1186/s12967-025-06370-0","pmcid":"PMC11916936","pmid":"40098172","title":"Prioritizing gut microbial SNPs linked to immunotherapy outcomes in NSCLC patients by integrative bioinformatics analysis."},{"doi":"10.1126/sciadv.aaz2299","pmcid":"PMC7176420","pmid":"32494636","title":"Metagenomic growth rate inferences of strains in situ."},{"doi":"10.1084/jem.20200606","pmcid":"PMC7664509","pmid":"33175106","title":"Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers."}],"sample_intervention_arms":{"drug_therapy":92,"no_intervention":127},"sex":{"female":47,"male":127},"title":"Gut mictobiota composition correlation with the clinical outcome of NSCLC and RCC patients treated with anti-PD-1 mAB","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB22863","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB22863_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB22863.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB22863.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB22863.csv.gz"}},{"accession":"PRJNA1469445","age_categories":{"unknown":218},"countries":{"RU":218},"first_public_year":"2026","gbp_per_sample_median":6.05,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"observational_with_procedure","intervention_detail":"Hospital therapy medications; stool sampled before admission and after discharge","interventions":["drug_therapy"],"n_samples":218,"papers":[],"sample_intervention_arms":{},"sex":{},"title":"WGS metagenomics data of stool samples of 109 patients and control group participants from 3 hospitals of Central Region of Russia","trial_population_condition":"unknown","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1469445","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1469445_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1469445.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1469445.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1469445.csv.gz"}},{"accession":"PRJNA1289847","age_categories":{"adult":216},"countries":{"CA":216},"first_public_year":"2025","gbp_per_sample_median":8.03,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":89},"intervention_design":"single_arm_before_after","intervention_detail":"Healthy donor FMT (oral capsules) plus anti-PD-1 ± anti-CTLA-4","interventions":["drug_therapy","fmt"],"n_samples":216,"papers":[{"doi":"10.1038/s41591-025-04186-5","pmcid":"PMC13099432","pmid":"41606121","title":"Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial."}],"sample_intervention_arms":{"fmt":214},"sex":{"female":5,"male":28},"title":"Gut microbiota composition of patients in FMT-LUMINate clinical trial","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1289847","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1289847_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1289847.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1289847.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1289847.csv.gz"}},{"accession":"PRJNA672867","age_categories":{"adult":134,"elderly":82},"countries":{"US":216},"first_public_year":"2020","gbp_per_sample_median":2.19,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"other_cancer":216},"intervention_design":"single_arm_before_after","intervention_detail":"Responder-derived FMT combined with anti-PD-1 therapy in refractory melanoma","interventions":["drug_therapy","fmt"],"n_samples":216,"papers":[{"doi":"10.1126/science.abf3363","pmcid":"PMC8097968","pmid":"33542131","title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients."},{"doi":"10.1371/journal.pone.0274633","pmcid":"PMC9477264","pmid":"36107983","title":"Time series strain tracking analysis post fecal transplantation identifies individual specific patterns of fecal dominant donor, recipient, and unrelated microbial strains."},{"doi":"10.1186/s12866-021-02312-0","pmcid":"PMC8454007","pmid":"34544375","title":"Incongruence between dominant commensal donor microbes in recipient feces post fecal transplant and response to anti-PD-1 immunotherapy."},{"doi":"10.1126/science.aaz7015","pmcid":"PMC8970537","pmid":"34941392","title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response."},{"doi":"10.1126/sciimmunol.abn0704","pmcid":"PMC9925043","pmid":"36083892","title":"The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer."}],"sample_intervention_arms":{"fmt":167,"no_intervention":49},"sex":{"female":65,"male":151},"title":"Effectiveness of Fecal Microbiota Transplant together with PD-1 blockade in overcoming resistance to anti-PD-1 therapy in advanced melanoma patients","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA672867","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA672867_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA672867.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA672867.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA672867.csv.gz"}},{"accession":"PRJNA1071720","age_categories":{"unknown":209},"countries":{"NL":209},"first_public_year":"2024","gbp_per_sample_median":0.29,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":false,"health_conditions":{"healthy_control":27,"ulcerative_colitis":182},"intervention_design":"randomized_controlled_trial","intervention_detail":"Budesonide or placebo pretreatment then 4 FMT infusions from selected donors","interventions":["drug_therapy","fmt"],"n_samples":209,"papers":[{"doi":"10.1093/ecco-jcc/jjae043","pmcid":"PMC11369067","pmid":"38572716","title":"Fecal Microbiota Transplantation engraftment after budesonide or placebo in patients with active ulcerative colitis using pre-selected donors: a randomized pilot study."},{"doi":"10.1093/ecco-jcc/jjae137","pmcid":"PMC11836888","pmid":"39225490","title":"Dynamics of Gut Microbiota After Fecal Microbiota Transplantation in Ulcerative Colitis: Success Linked to Control of Prevotellaceae."},{"doi":"10.1093/ismeco/ycaf119","pmcid":"PMC12378841","pmid":"40873786","title":"Ecological resilience in ulcerative colitis: microbial dynamics of donor and resident species in a longitudinal fecal microbiota transplantation study."},{"doi":"10.1038/s41467-026-73290-y","pmcid":"PMC13376552","pmid":"42151161","title":"Inorganic nitrogen metabolic reprogramming of the gut microbiome drives fecal microbiota transplantation in ulcerative colitis."}],"sample_intervention_arms":{},"sex":{},"title":"FECBUD Study Fecal Metagenomes","trial_population_condition":"ulcerative_colitis","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1071720","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1071720_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1071720.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1071720.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1071720.csv.gz"}},{"accession":"PRJEB44907","age_categories":{"unknown":208},"countries":{"CN":208},"first_public_year":"2021","gbp_per_sample_median":2.99,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"randomized_controlled_trial","intervention_detail":"Berberine and/or Bifidobacterium vs placebo, 16-week RCT","interventions":["drug_therapy","probiotic"],"n_samples":208,"papers":[{"doi":"10.1186/s13073-021-00942-7","pmcid":"PMC8351344","pmid":"34365978","title":"Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study."}],"sample_intervention_arms":{},"sex":{},"title":"Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: A multi-center, double-blind, randomized, parallel-controlled study","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB44907","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB44907_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB44907.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB44907.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB44907.csv.gz"}},{"accession":"PRJEB39500","age_categories":{"adult":203},"countries":{"LV":203},"first_public_year":"2021","gbp_per_sample_median":0.95,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":false,"health_conditions":{"healthy_control":103,"type2_diabetes":100},"intervention_design":"single_arm_before_after","intervention_detail":"Metformin 2x850mg/day; healthy and newly-diagnosed T2D patients sampled over time","interventions":["drug_therapy"],"n_samples":203,"papers":[{"doi":"10.1371/journal.pone.0241338","pmcid":"PMC7598494","pmid":"33125401","title":"Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients."},{"doi":"10.1128/mbio.00169-24","pmcid":"PMC11237675","pmid":"38767350","title":"Changes in the type 2 diabetes gut mycobiome associate with metformin treatment across populations."}],"sample_intervention_arms":{"drug_therapy":203},"sex":{},"title":"Baseline gut microbiome composition predicts metformin therapy short term efficacy in newly diagnosed type 2 diabetes patients","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB39500","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB39500_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB39500.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB39500.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB39500.csv.gz"}},{"accession":"PRJEB12124","age_categories":{"adult":186,"elderly":2},"countries":{"CN":188},"first_public_year":"2016","gbp_per_sample_median":5.7,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"type2_diabetes":188},"intervention_design":"randomized_controlled_trial","intervention_detail":"Acarbose vs Glipizide (sulfonylurea) oral antidiabetic drugs in treatment-naive T2D patients","interventions":["drug_therapy"],"n_samples":188,"papers":[{"doi":"10.1038/s41467-017-01682-2","pmcid":"PMC5702614","pmid":"29176714","title":"Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment."},{"doi":"10.1128/mbio.00095-20","pmcid":"PMC7157763","pmid":"32265336","title":"Synergy between Cell Surface Glycosidases and Glycan-Binding Proteins Dictates the Utilization of Specific Beta(1,3)-Glucans by Human Gut Bacteroides."},{"doi":"10.1128/mbio.03628-20","pmcid":"PMC8262883","pmid":"34061597","title":"Human Gut Faecalibacterium prausnitzii Deploys a Highly Efficient Conserved System To Cross-Feed on β-Mannan-Derived Oligosaccharides."},{"doi":"10.1016/j.chom.2022.02.001","pmcid":"PMC9096808","pmid":"35240043","title":"Diverse events have transferred genes for edible seaweed digestion from marine to human gut bacteria."},{"doi":"10.1038/s41467-024-47272-x","pmcid":"PMC11009399","pmid":"38605009","title":"Plasmids in the human gut reveal neutral dispersal and recombination that is overpowered by inflammatory diseases."}],"sample_intervention_arms":{"drug_therapy":94},"sex":{"female":72,"male":116},"title":"Gut microbiome-dependent stratification of patients for anti-diabetic treatment","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB12124","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB12124_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB12124.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB12124.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB12124.csv.gz"}},{"accession":"PRJNA532645","age_categories":{"adolescent":112,"adult":18,"child":51,"infant":5},"countries":{"CA":4,"FI":1,"IL":120,"IT":15},"first_public_year":"2019","gbp_per_sample_median":0.47,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"ulcerative_colitis":186},"intervention_design":"unknown","intervention_detail":"","interventions":[],"n_samples":186,"papers":[{"doi":"10.1016/j.isci.2024.111442","pmcid":"PMC11650326","pmid":"39691780","title":"Gut-microbiota-based ensemble model predicts prognosis of pediatric inflammatory bowel disease."},{"doi":"10.1016/j.chom.2025.01.002","pmcid":"PMC12268991","pmid":"39947133","title":"A meta-analysis of the gut microbiome in inflammatory bowel disease patients identifies disease-associated small molecules."}],"sample_intervention_arms":{"antibiotic":78,"drug_therapy":108},"sex":{"female":98,"male":88},"title":"PRASCO gut microbiome profile of Pediatric Severe Acute Ulcerative Colitis patients under Antimicrobial treatment","trial_population_condition":"unknown","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA532645","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA532645_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA532645.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA532645.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA532645.csv.gz"}},{"accession":"PRJNA826552","age_categories":{"adult":173,"elderly":8},"countries":{"CN":181},"first_public_year":"2022","gbp_per_sample_median":9.26,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"type2_diabetes":181},"intervention_design":"randomized_controlled_trial","intervention_detail":"Acarbose vs vildagliptin, 24-week RCT in T2D patients","interventions":["drug_therapy"],"n_samples":181,"papers":[{"doi":"10.1007/s00125-022-05768-5","pmcid":"PMC9477956","pmid":"35930018","title":"Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised tr"},{"doi":"10.1002/imt2.179","pmcid":"PMC11170963","pmid":"38882498","title":"Deciphering unique and shared interactions between the human gut microbiota and oral antidiabetic drugs."}],"sample_intervention_arms":{"drug_therapy":82,"no_intervention":82},"sex":{"female":72,"male":92},"title":"human gut metagenome Raw sequence reads","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA826552","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA826552_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA826552.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA826552.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA826552.csv.gz"}},{"accession":"PRJNA384246","age_categories":{"adult":159,"elderly":15},"countries":{"US":174},"first_public_year":"2019","gbp_per_sample_median":2.66,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"crohns_disease":88,"ulcerative_colitis":86},"intervention_design":"single_arm_before_after","intervention_detail":"Vedolizumab therapy in IBD patients, sampled over treatment","interventions":["drug_therapy"],"n_samples":174,"papers":[{"doi":"10.1038/s41579-019-0213-6","pmcid":"PMC6759048","pmid":"31249397","title":"Microbial genes and pathways in inflammatory bowel disease."},{"doi":"10.1186/s12864-020-6749-z","pmcid":"PMC7216530","pmid":"32393180","title":"Host DNA contents in fecal metagenomics as a biomarker for intestinal diseases and effective treatment."},{"doi":"10.1016/j.chom.2025.01.002","pmcid":"PMC12268991","pmid":"39947133","title":"A meta-analysis of the gut microbiome in inflammatory bowel disease patients identifies disease-associated small molecules."}],"sample_intervention_arms":{},"sex":{"female":84,"male":90},"title":"Studies of metagenomes of inflammatory bowel disease patient receiving vedolizamub therapy","trial_population_condition":"ibd_unspecified","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA384246","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA384246_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA384246.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA384246.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA384246.csv.gz"}},{"accession":"PRJEB43454","age_categories":{"adult":170},"countries":{"GB":112,"NL":58},"first_public_year":"2022","gbp_per_sample_median":2.89,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"gi_infection_or_diarrhoea":170},"intervention_design":"single_arm_before_after","intervention_detail":"Diosmectite 3g/sachet x3/day for 5 weeks in chronic diarrhea","interventions":["drug_therapy"],"n_samples":170,"papers":[{"doi":"10.1186/s12866-022-02464-7","pmcid":"PMC8840705","pmid":"35151268","title":"Long-term diosmectite use does not alter the gut microbiota in adults with chronic diarrhea."}],"sample_intervention_arms":{"drug_therapy":70,"no_intervention":100},"sex":{"female":74,"male":96},"title":"Long-term diosmectite use does not alter the gut microbiota in adults with chronic diarrhea","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB43454","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB43454_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB43454.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB43454.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB43454.csv.gz"}},{"accession":"PRJEB72523","age_categories":{"adult":115,"elderly":48},"countries":{"IT":163},"first_public_year":"2025","gbp_per_sample_median":4.28,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"colorectal_cancer":163},"intervention_design":"randomized_controlled_trial","intervention_detail":"Atezolizumab added to FOLFOXIRI plus bevacizumab in mCRC","interventions":["drug_therapy"],"n_samples":163,"papers":[{"doi":"10.1038/s41591-025-03693-9","pmcid":"PMC12283368","pmid":"40461820","title":"Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer."}],"sample_intervention_arms":{},"sex":{"female":67,"male":96},"title":"Gut microbiome samples from the AtezoTRIBE phase-II clinical trial","trial_population_condition":"colorectal_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB72523","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB72523_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB72523.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB72523.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB72523.csv.gz"}},{"accession":"PRJNA1430386","age_categories":{"unknown":163},"countries":{"CA":160,"US":3},"first_public_year":"2026","gbp_per_sample_median":3.89,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"colorectal_cancer":7,"crohns_disease":16,"neurological_psychiatric":11,"other_cancer":41,"other_disease":22},"intervention_design":"observational_with_procedure","intervention_detail":"","interventions":[],"n_samples":163,"papers":[],"sample_intervention_arms":{"drug_therapy":35,"no_intervention":43},"sex":{"female":20,"male":55},"title":"Impact of bladder microbiome on BCG response","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1430386","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1430386_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1430386.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1430386.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1430386.csv.gz"}},{"accession":"PRJEB91542","age_categories":{"adult":159},"countries":{"NL":159},"first_public_year":"2025","gbp_per_sample_median":6.58,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"colorectal_cancer":68,"other_cancer":91},"intervention_design":"observational_with_procedure","intervention_detail":"Nivolumab immune checkpoint blockade therapy","interventions":["drug_therapy"],"n_samples":159,"papers":[{"doi":"10.1158/2159-8290.cd-24-1669","pmcid":null,"pmid":"40996449","title":"Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy."}],"sample_intervention_arms":{"drug_therapy":77,"no_intervention":82},"sex":{"female":57,"male":41},"title":"Microbial metabolic pathways guide response to immune checkpoint blockade therapy","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB91542","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB91542_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB91542.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB91542.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB91542.csv.gz"}},{"accession":"PRJNA1171107","age_categories":{"adult":159},"countries":{"NL":159},"first_public_year":"2025","gbp_per_sample_median":8.85,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"colorectal_cancer":159},"intervention_design":"single_arm_before_after","intervention_detail":"Capecitabine chemotherapy, longitudinal stool sampling baseline/cycle3/post-treatment","interventions":["drug_therapy"],"n_samples":159,"papers":[{"doi":"10.1128/mbio.00930-25","pmcid":"PMC12153289","pmid":"40391895","title":"Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity."}],"sample_intervention_arms":{"drug_therapy":102,"no_intervention":57},"sex":{"female":2,"male":2},"title":"The gut microbiota is associated with capecitabine toxicity in colorectal cancer patients","trial_population_condition":"colorectal_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1171107","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1171107_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1171107.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1171107.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1171107.csv.gz"}},{"accession":"PRJEB28545","age_categories":{"unknown":150},"countries":{"CN":150},"first_public_year":"2019","gbp_per_sample_median":10.44,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":false,"health_conditions":{"autoimmune_inflammatory":112,"healthy_control":37},"intervention_design":"non_randomized_controlled","intervention_detail":"AS patients treated with NSAIDs (celecoxib) or Chinese herbal medicine vs untreated/healthy","interventions":["drug_therapy"],"n_samples":150,"papers":[{"doi":"10.1099/jmm.0.001107","pmcid":"PMC7451032","pmid":"31778109","title":"Metagenome-wide association study of the alterations in the intestinal microbiome composition of ankylosing spondylitis patients and the effect of traditional and herbal treatment."},{"doi":"10.3389/fimmu.2023.1154380","pmcid":"PMC10098016","pmid":"37063855","title":"Alterations in the gut virome in patients with ankylosing spondylitis."}],"sample_intervention_arms":{},"sex":{},"title":"Meta cooperation project of guangdong provincial hospital of traditional Chinese medicine","trial_population_condition":"autoimmune_inflammatory","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB28545","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB28545_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB28545.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB28545.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB28545.csv.gz"}},{"accession":"PRJNA1335605","age_categories":{"unknown":146},"countries":{"HK":146},"first_public_year":"2025","gbp_per_sample_median":5.42,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"ibs":146},"intervention_design":"single_arm_before_after","intervention_detail":"CDD2101 granules treatment in IBS-C patients","interventions":["drug_therapy"],"n_samples":146,"papers":[],"sample_intervention_arms":{},"sex":{},"title":"Efficacy and Mechanisms of CDD2101 granules on constipation predominant irritable bowel syndrome (IBS-C)","trial_population_condition":"ibs","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1335605","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1335605_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1335605.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1335605.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1335605.csv.gz"}},{"accession":"PRJNA1491285","age_categories":{"adult":64,"elderly":79},"countries":{"US":143},"first_public_year":"2026","gbp_per_sample_median":0.77,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"liver_disease":143},"intervention_design":"single_arm_before_after","intervention_detail":"Lactulose given to cirrhosis patients, sampled at baseline and 4 weeks","interventions":["drug_therapy"],"n_samples":143,"papers":[],"sample_intervention_arms":{},"sex":{"female":114,"male":29},"title":"Gut microbiota in patients with cirrhosis and portal hypertension receiving lactulose","trial_population_condition":"liver_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1491285","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1491285_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1491285.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1491285.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1491285.csv.gz"}},{"accession":"PRJDB41627","age_categories":{"unknown":142},"countries":{},"first_public_year":"2026","gbp_per_sample_median":10.17,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"randomized_controlled_trial","intervention_detail":"Semaglutide (GLP-1 RA) vs high dietary fiber in obese subjects; FMT to germ-free mice","interventions":["drug_therapy","prebiotic_or_fibre"],"n_samples":142,"papers":[{"doi":"10.64898/2026.05.02.26352300","pmcid":null,"pmid":null,"title":"GLP-1 RA-Exacerbated Gut Microbiome Dysbiosis in Obesity Mediates Post-Cessation Weight Regain"}],"sample_intervention_arms":{},"sex":{},"title":"GLP-1 RAs or dietary fiber interventions study (PRJCA050830)","trial_population_condition":"obesity","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJDB41627","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJDB41627_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJDB41627.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJDB41627.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJDB41627.csv.gz"}},{"accession":"PRJEB103799","age_categories":{"child":140},"countries":{"ES":140},"first_public_year":"2026","gbp_per_sample_median":0.96,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_disease":140},"intervention_design":"single_arm_before_after","intervention_detail":"CFTR modulator elexacaftor/tezacaftor/ivacaftor (ETI), baseline vs 12 months therapy","interventions":["drug_therapy"],"n_samples":140,"papers":[],"sample_intervention_arms":{},"sex":{"female":64,"male":76},"title":"Shotgun metagenomic sequencing of gut and respiratory microbiota in cystic fibrosis patients before and after CFTR modulator therapy","trial_population_condition":"other_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB103799","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB103799_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB103799.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB103799.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB103799.csv.gz"}},{"accession":"PRJNA741822","age_categories":{"adult":123},"countries":{"CN":123},"first_public_year":"2022","gbp_per_sample_median":10.94,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{},"intervention_design":"randomized_controlled_trial","intervention_detail":"Probio-M8 probiotic + atorvastatin/metoprolol vs placebo + atorvastatin/metoprolol, 6 months","interventions":["drug_therapy","probiotic"],"n_samples":123,"papers":[{"doi":"10.1128/msystems.00100-22","pmcid":"PMC9040731","pmid":"35343796","title":"Bifidobacterium lactis Probio-M8 Adjuvant Treatment Confers Added Benefits to Patients with Coronary Artery Disease via Target Modulation of the Gut-Heart/-Brain Axes."}],"sample_intervention_arms":{"placebo":51,"probiotic":72},"sex":{},"title":"Genome level reveals that probiotics supplementation can alleviate the clinical symptoms of patients with coronary heart disease","trial_population_condition":"cardiometabolic_other","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA741822","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA741822_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA741822.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA741822.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA741822.csv.gz"}},{"accession":"PRJNA439152","age_categories":{"unknown":119},"countries":{"CN":119},"first_public_year":"2022","gbp_per_sample_median":0.06,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"ulcerative_colitis":119},"intervention_design":"non_randomized_controlled","intervention_detail":"5-aminosalicylic acid (5-ASA) treatment vs untreated UC patients","interventions":["drug_therapy"],"n_samples":119,"papers":[{"doi":"10.3389/fmicb.2018.01274","pmcid":"PMC6008376","pmid":"29951050","title":"5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis."}],"sample_intervention_arms":{"drug_therapy":19,"no_intervention":20},"sex":{},"title":"GUT BACTERIAL METAGENOME Metagenome","trial_population_condition":"ulcerative_colitis","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA439152","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA439152_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA439152.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA439152.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA439152.csv.gz"}},{"accession":"PRJNA1194543","age_categories":{"unknown":114},"countries":{"PE":114},"first_public_year":"2025","gbp_per_sample_median":6.76,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":false,"health_conditions":{"healthy_control":71,"other_infection":43},"intervention_design":"single_arm_before_after","intervention_detail":"Triclabendazole (TCBZ) treatment for F. hepatica infection, pre/post sampling","interventions":["drug_therapy"],"n_samples":114,"papers":[{"doi":"10.3389/fcimb.2025.1555171","pmcid":"PMC11931013","pmid":"40129931","title":"Distinct gut microbiome features characterize <i>Fasciola hepatica</i> infection and predict triclabendazole treatment outcomes in Peruvian patients."}],"sample_intervention_arms":{},"sex":{"female":75,"male":39},"title":"Human gut microbiome association with Fasciola Hepatica infection in Peru","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1194543","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1194543_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1194543.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1194543.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1194543.csv.gz"}},{"accession":"PRJNA685168","age_categories":{"adult":102,"elderly":12},"countries":{"US":114},"first_public_year":"2021","gbp_per_sample_median":2.9,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"crohns_disease":65,"ulcerative_colitis":49},"intervention_design":"observational_with_procedure","intervention_detail":"Anti-TNF, anti-IL12/23, or anti-integrin biologic therapy","interventions":["drug_therapy"],"n_samples":114,"papers":[{"doi":"10.1016/j.chom.2021.06.019","pmcid":"PMC8366279","pmid":"34297922","title":"Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease."},{"doi":"10.1016/j.chom.2024.05.022","pmcid":"PMC11239293","pmid":"38917808","title":"Discovery of disease-adapted bacterial lineages in inflammatory bowel diseases."},{"doi":"10.1016/j.chom.2025.01.002","pmcid":"PMC12268991","pmid":"39947133","title":"A meta-analysis of the gut microbiome in inflammatory bowel disease patients identifies disease-associated small molecules."}],"sample_intervention_arms":{"drug_therapy":114},"sex":{"female":59,"male":55},"title":"Multi-omics suggest diverse mechanisms for response to biologic therapies in IBD","trial_population_condition":"ibd_unspecified","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA685168","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA685168_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA685168.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA685168.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA685168.csv.gz"}},{"accession":"PRJNA948536","age_categories":{"adolescent":25,"adult":2,"child":86,"infant":1},"countries":{"US":114},"first_public_year":"2023","gbp_per_sample_median":3.82,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_disease":114},"intervention_design":"single_arm_before_after","intervention_detail":"Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) CFTR modulator therapy","interventions":["drug_therapy"],"n_samples":114,"papers":[{"doi":"10.1128/mbio.01935-23","pmcid":"PMC10865789","pmid":"38275294","title":"Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor."}],"sample_intervention_arms":{},"sex":{"female":49,"male":65},"title":"CF patient gut microbiome investigation with CFTR modulator therapy","trial_population_condition":"other_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA948536","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA948536_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA948536.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA948536.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA948536.csv.gz"}},{"accession":"PRJNA1107274","age_categories":{"adult":65,"elderly":48},"countries":{"US":113},"first_public_year":"2024","gbp_per_sample_median":7.24,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"other_cancer":113},"intervention_design":"single_arm_before_after","intervention_detail":"Neoadjuvant TLR9 agonist vidutolimod plus anti-PD-1 nivolumab","interventions":["drug_therapy"],"n_samples":113,"papers":[{"doi":"10.1016/j.ccell.2024.10.007","pmcid":"PMC11560503","pmid":"39486411","title":"Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial."}],"sample_intervention_arms":{"drug_therapy":87,"no_intervention":26},"sex":{"female":45,"male":68},"title":"Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1107274","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1107274_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1107274.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1107274.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1107274.csv.gz"}},{"accession":"PRJNA1290813","age_categories":{"adult":113},"countries":{"CA":113},"first_public_year":"2025","gbp_per_sample_median":15.12,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":113},"intervention_design":"single_arm_before_after","intervention_detail":"Encapsulated donor FMT plus ICI therapy (ipilimumab/nivolumab or pembrolizumab combos)","interventions":["drug_therapy","fmt"],"n_samples":113,"papers":[{"doi":"10.1038/s41591-025-04183-8","pmcid":"PMC13099417","pmid":"41606120","title":"Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial."}],"sample_intervention_arms":{},"sex":{},"title":"FMT plus systemic therapy in renal cell cancer","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1290813","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1290813_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1290813.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1290813.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1290813.csv.gz"}},{"accession":"PRJNA1427647","age_categories":{"adult":113},"countries":{"US":113},"first_public_year":"2026","gbp_per_sample_median":15.81,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"observational_with_procedure","intervention_detail":"Oral methotrexate in treatment-naive RA patients","interventions":["drug_therapy"],"n_samples":113,"papers":[],"sample_intervention_arms":{},"sex":{},"title":"Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naive Early Rheumatoid Arthritis Patients","trial_population_condition":"autoimmune_inflammatory","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1427647","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1427647_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1427647.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1427647.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1427647.csv.gz"}},{"accession":"PRJEB49516","age_categories":{"adult":68,"elderly":39},"countries":{"AU":107},"first_public_year":"2024","gbp_per_sample_median":6.15,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":107},"intervention_design":"single_arm_before_after","intervention_detail":"Combination ipilimumab and nivolumab immune checkpoint blockade in rare cancers","interventions":["drug_therapy"],"n_samples":107,"papers":[{"doi":"10.1038/s41591-024-02823-z","pmcid":"PMC10957475","pmid":"38429524","title":"A gut microbial signature for combination immune checkpoint blockade across cancer types."},{"doi":"10.1016/j.isci.2025.112162","pmcid":"PMC11937697","pmid":"40151642","title":"Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types."},{"doi":"10.1002/advs.202520095","pmcid":"PMC13334858","pmid":"41972457","title":"A Microbial Lipid-ATP Synthase Axis Fuels NK Cell Antitumor Activity."},{"doi":"10.1080/19490976.2026.2662690","pmcid":"PMC13114121","pmid":"42026803","title":"Gene-level gut microbiome signatures as predictive biomarkers for response to immune checkpoint inhibitors across multiple cancer types."},{"doi":"10.34133/csbj.0065","pmcid":"PMC13173278","pmid":"42146906","title":"Ecological and Functional Stratification of the Stool Microbiome Predicts Response to Immune Checkpoint Inhibitors across Cancer Types."}],"sample_intervention_arms":{},"sex":{"female":68,"male":36},"title":"Role_of_microbiome_in_rare_cancers_in_Australia","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB49516","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB49516_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB49516.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB49516.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB49516.csv.gz"}},{"accession":"PRJNA1206184","age_categories":{"adult":107},"countries":{"NO":107},"first_public_year":"2025","gbp_per_sample_median":5.96,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":false,"health_conditions":{"healthy_control":47,"transplant_or_immunocompromised":60},"intervention_design":"observational_with_procedure","intervention_detail":"Kidney transplantation with post-transplant mycophenolate mofetil immunosuppression; samples pre/post-transplant","interventions":["drug_therapy","surgery"],"n_samples":107,"papers":[{"doi":"10.1186/s40168-025-02142-6","pmcid":"PMC12291295","pmid":"40707990","title":"Microbiome-derived reactivation of mycophenolate explains variations in enterohepatic recirculation in kidney transplant recipients."}],"sample_intervention_arms":{},"sex":{},"title":"Mediation of systemic exposure to the immunosuppressive drug Mycophenolate mofetil by the gut microbiome in kidney transplant patients","trial_population_condition":"transplant_or_immunocompromised","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1206184","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1206184_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1206184.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1206184.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1206184.csv.gz"}},{"accession":"PRJNA978931","age_categories":{"adult":101},"countries":{"US":101},"first_public_year":"2024","gbp_per_sample_median":21.61,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":101},"intervention_design":"randomized_controlled_trial","intervention_detail":"SER-401 spore formulation + vancomycin preconditioning + nivolumab vs placebo, melanoma","interventions":["antibiotic","drug_therapy","live_biotherapeutic"],"n_samples":101,"papers":[{"doi":"10.1158/2159-8290.cd-24-0066","pmcid":"PMC11215408","pmid":"38588588","title":"Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity."}],"sample_intervention_arms":{},"sex":{},"title":"Microbiome intervention with SER-401 prior to nivolumab for unresectable or metastatic melanoma: a randomized placebo-controlled, biomarker-stratified multicenter phase 1b trial","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA978931","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA978931_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA978931.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA978931.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA978931.csv.gz"}},{"accession":"PRJNA715947","age_categories":{"unknown":99},"countries":{"CN":99},"first_public_year":"2021","gbp_per_sample_median":0.21,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"single_arm_before_after","intervention_detail":"First-line anti-tuberculosis drug treatment, fecal sampling at multiple time points (0, 2, 6 months)","interventions":["drug_therapy"],"n_samples":99,"papers":[{"doi":"10.1128/spectrum.00615-21","pmcid":"PMC8672887","pmid":"34908436","title":"Gut Mycobiota Dysbiosis in Pulmonary Tuberculosis Patients Undergoing Anti-Tuberculosis Treatment."},{"doi":"10.1002/cam4.6503","pmcid":"PMC10557844","pmid":"37676050","title":"Identification of microbial markers associated with lung cancer based on multi-cohort 16 s rRNA analyses: A systematic review and meta-analysis."}],"sample_intervention_arms":{},"sex":{},"title":"Gut microbiota and tuberculosis","trial_population_condition":"other_infection","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA715947","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA715947_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA715947.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA715947.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA715947.csv.gz"}},{"accession":"PRJNA944403","age_categories":{"adult":99},"countries":{"CN":99},"first_public_year":"2024","gbp_per_sample_median":6.77,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"cardiometabolic_other":99},"intervention_design":"single_arm_before_after","intervention_detail":"Amiodarone taken for 90 days, sampled at 0/4/14/30/90 days","interventions":["drug_therapy"],"n_samples":99,"papers":[],"sample_intervention_arms":{},"sex":{},"title":"human cohort studies of amiodarone induced gut microbial disorder","trial_population_condition":"cardiometabolic_other","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA944403","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA944403_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA944403.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA944403.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA944403.csv.gz"}},{"accession":"PRJNA762360","age_categories":{"adult":28,"elderly":66},"countries":{"US":94},"first_public_year":"2022","gbp_per_sample_median":8.9,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"other_cancer":65,"other_disease":29},"intervention_design":"none","intervention_detail":"","interventions":[],"n_samples":94,"papers":[{"doi":"10.1136/jitc-2026-015617","pmcid":"PMC13384208","pmid":"42463281","title":"<i>Blautia coccoides</i>-derived acetate potentiates anti-PD-1 immunotherapy in melanoma by activating cytotoxic CD8<sup>+</sup> T cells."},{"doi":"10.1038/s41591-022-01698-2","pmcid":"PMC10246505","pmid":"35228752","title":"Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1."},{"doi":"10.18632/oncotarget.28252","pmcid":"PMC9295706","pmid":"35875611","title":"Predicting cancer immunotherapy response from gut microbiomes using machine learning models."},{"doi":"10.1126/sciimmunol.abn0704","pmcid":"PMC9925043","pmid":"36083892","title":"The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer."},{"doi":"10.1038/s41467-023-42997-7","pmcid":"PMC10654443","pmid":"37973916","title":"Gut microbial structural variation associates with immune checkpoint inhibitor response."}],"sample_intervention_arms":{"drug_therapy":67,"no_intervention":27},"sex":{"female":28,"male":66},"title":"Intestinal Microbiota Signatures Predict Clinical Outcome and Immune-related Adverse Events in PD-1 Treated Melanoma Patients","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA762360","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA762360_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA762360.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA762360.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA762360.csv.gz"}},{"accession":"PRJNA413659","age_categories":{"adult":81,"elderly":11},"countries":{"RU":92},"first_public_year":"2017","gbp_per_sample_median":1.42,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"gi_infection_or_diarrhoea":92},"intervention_design":"single_arm_before_after","intervention_detail":"Quadruple HP eradication: amoxicillin, clarithromycin, PPI, bismuth subsalicylate","interventions":["antibiotic","drug_therapy"],"n_samples":92,"papers":[{"doi":"10.3389/fmicb.2019.01902","pmcid":"PMC6718723","pmid":"31507546","title":"Shifts in the Human Gut Microbiota Structure Caused by Quadruple Helicobacter pylori Eradication Therapy."}],"sample_intervention_arms":{},"sex":{"female":46,"male":46},"title":"Shifts of the intestinal microbiota and resistome caused by Helicobacter pylori eradication therapy","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA413659","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA413659_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA413659.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA413659.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA413659.csv.gz"}},{"accession":"PRJEB88212","age_categories":{"unknown":90},"countries":{"NO":90},"first_public_year":"2025","gbp_per_sample_median":4.54,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":false,"health_conditions":{"crohns_disease":32,"healthy_control":26,"ulcerative_colitis":32},"intervention_design":"single_arm_before_after","intervention_detail":"IBD treatment, faecal samples before and after","interventions":["drug_therapy"],"n_samples":90,"papers":[{"doi":"10.1186/s12866-026-05101-9","pmcid":"PMC13255511","pmid":"42045813","title":"Exploring alterations in the gut resistome in medically treated inflammatory bowel disease patients."}],"sample_intervention_arms":{},"sex":{},"title":"Shotgun microbiome sequencing of faecal contents from IBD patients, before and after treatment","trial_population_condition":"ibd_unspecified","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB88212","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB88212_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB88212.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB88212.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB88212.csv.gz"}},{"accession":"PRJDB43083","age_categories":{"adult":89},"countries":{"IL":89},"first_public_year":"2026","gbp_per_sample_median":3.14,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"crohns_disease":89},"intervention_design":"observational_with_procedure","intervention_detail":"Biologic therapies for Crohn's disease, treatment-associated signatures","interventions":["drug_therapy"],"n_samples":89,"papers":[],"sample_intervention_arms":{},"sex":{},"title":"Stool shotgun metagenomes from patients with Crohn's disease receiving biologic therapies","trial_population_condition":"crohns_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJDB43083","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJDB43083_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJDB43083.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJDB43083.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJDB43083.csv.gz"}},{"accession":"PRJNA1203401","age_categories":{"adult":78,"elderly":9},"countries":{"HK":87},"first_public_year":"2025","gbp_per_sample_median":12.04,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"liver_disease":87},"intervention_design":"single_arm_before_after","intervention_detail":"Empagliflozin treatment, baseline to week 52, in MASLD patients","interventions":["drug_therapy"],"n_samples":87,"papers":[{"doi":"10.1111/liv.70023","pmcid":"PMC11827547","pmid":"39950834","title":"Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes Mellitus."}],"sample_intervention_arms":{},"sex":{},"title":"Gut microbiota predicts treatment response to empagliflozin among MASLD patients without diabetes mellitus","trial_population_condition":"liver_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1203401","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1203401_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1203401.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1203401.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1203401.csv.gz"}},{"accession":"PRJNA1291832","age_categories":{"adult":33,"elderly":54},"countries":{"AU":87},"first_public_year":"2025","gbp_per_sample_median":7.33,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"other_cancer":87},"intervention_design":"none","intervention_detail":"","interventions":[],"n_samples":87,"papers":[],"sample_intervention_arms":{"drug_therapy":48,"no_intervention":39},"sex":{"female":36,"male":51},"title":"Shotgun metagenomics data of melanoma patients undergoing ICB","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1291832","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1291832_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1291832.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1291832.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1291832.csv.gz"}},{"accession":"PRJEB72522","age_categories":{"adult":86},"countries":{"IT":86},"first_public_year":"2026","gbp_per_sample_median":4.94,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"single_arm_before_after","intervention_detail":"Temozolomide priming in MSS mCRC patients, sampled before/after","interventions":["drug_therapy"],"n_samples":86,"papers":[],"sample_intervention_arms":{},"sex":{},"title":"ARETHUSA oral and stool microbiome samples from MSS/MSI-H mCRC patients","trial_population_condition":"colorectal_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB72522","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB72522_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB72522.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB72522.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB72522.csv.gz"}},{"accession":"PRJNA1240691","age_categories":{"adult":63,"elderly":12},"countries":{"CN":75},"first_public_year":"2025","gbp_per_sample_median":6.97,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"ulcerative_colitis":75},"intervention_design":"single_arm_before_after","intervention_detail":"5-aminosalicylic acid (5-ASA) standardized treatment for UC","interventions":["drug_therapy"],"n_samples":75,"papers":[{"doi":"10.1016/j.isci.2025.112568","pmcid":"PMC12159923","pmid":"40510115","title":"Gut microbiome signatures predict 5-ASA efficacy in ulcerative colitis."}],"sample_intervention_arms":{},"sex":{},"title":"Gut metagenome","trial_population_condition":"ulcerative_colitis","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1240691","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1240691_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1240691.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1240691.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1240691.csv.gz"}},{"accession":"PRJNA627223","age_categories":{"unknown":75},"countries":{"US":75},"first_public_year":"2020","gbp_per_sample_median":1.23,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"other_infection":75},"intervention_design":"single_arm_before_after","intervention_detail":"Antiretroviral therapy (ART) initiation, sampled baseline/24wk/48wk","interventions":["drug_therapy"],"n_samples":75,"papers":[],"sample_intervention_arms":{"drug_therapy":48,"no_intervention":27},"sex":{},"title":"Shotgun - HIV Intestinal Microbiota Pre and Post Initiation of Antiretroviral Therapy.","trial_population_condition":"unknown","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA627223","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA627223_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA627223.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA627223.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA627223.csv.gz"}},{"accession":"PRJNA1470177","age_categories":{"adult":74},"countries":{"IN":74},"first_public_year":"2026","gbp_per_sample_median":0.22,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"type2_diabetes":74},"intervention_design":"randomized_controlled_trial","intervention_detail":"Mustadi Ghana Vati, Varadi Ghana Vati (herbal formulations) or Metformin","interventions":["drug_therapy"],"n_samples":74,"papers":[],"sample_intervention_arms":{"drug_therapy":74},"sex":{},"title":"Changes in the Gut Microbiome Following Mustadi Ghana Vati, Varadi Ghana Vati and Metformin Interventions in Type 2 Diabetes: A 24-Week Baseline to Post-Treatment Analysis","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1470177","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1470177_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1470177.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1470177.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1470177.csv.gz"}},{"accession":"PRJEB42384","age_categories":{"unknown":73},"countries":{"ES":73},"first_public_year":"2022","gbp_per_sample_median":2.96,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_infection":73},"intervention_design":"single_arm_before_after","intervention_detail":"MVA.HIVconsv therapeutic vaccine plus romidepsin latency-reversing agent","interventions":["drug_therapy","vaccine"],"n_samples":73,"papers":[{"doi":"10.1186/s40168-022-01247-6","pmcid":"PMC9004083","pmid":"35410461","title":"Gut microbiome signatures linked to HIV-1 reservoir size and viremia control."}],"sample_intervention_arms":{},"sex":{},"title":"BCN02_ROMI_Microbiome","trial_population_condition":"unknown","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB42384","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB42384_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB42384.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB42384.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB42384.csv.gz"}},{"accession":"PRJEB86263","age_categories":{"adult":72},"countries":{"DE":72},"first_public_year":"2025","gbp_per_sample_median":10.06,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"other_disease":72},"intervention_design":"single_arm_before_after","intervention_detail":"12 weeks gender-affirming hormonal therapy, pre/post sampling in trans individuals","interventions":["drug_therapy"],"n_samples":72,"papers":[{"doi":"10.1186/s12916-024-03548-z","pmcid":"PMC11367877","pmid":"39218875","title":"Gender-affirming hormonal therapy induces a gender-concordant fecal metagenome transition in transgender individuals."},{"doi":"10.1186/s12916-025-04144-5","pmcid":"PMC12117967","pmid":"40426218","title":"Correction: Gender-affirming hormonal therapy induces a gender-concordant fecal metagenome transition in transgender individuals."}],"sample_intervention_arms":{"drug_therapy":36,"no_intervention":36},"sex":{},"title":"Gender-affirming hormonal therapy induces a gender-concordant fecal metagenome transition in transgender individuals.","trial_population_condition":"other_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB86263","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB86263_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB86263.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB86263.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB86263.csv.gz"}},{"accession":"PRJNA806510","age_categories":{"adult":72},"countries":{"CN":72},"first_public_year":"2025","gbp_per_sample_median":10.58,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"type2_diabetes":72},"intervention_design":"observational_with_procedure","intervention_detail":"Metformin monotherapy in newly diagnosed T2DM patients","interventions":["drug_therapy"],"n_samples":72,"papers":[{"doi":"10.1016/j.apsb.2025.02.008","pmcid":"PMC12145038","pmid":"40487637","title":"A critical role for <i>Phocaeicola vulgatus</i> in negatively impacting metformin response in diabetes."}],"sample_intervention_arms":{"drug_therapy":22,"no_intervention":28},"sex":{"female":5,"male":5},"title":"Study of Gut Microbiota Mediated Metformin Monotherapy Failure in Type 2 Diabetes Mellitus","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA806510","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA806510_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA806510.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA806510.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA806510.csv.gz"}},{"accession":"PRJNA494824","age_categories":{"adult":68,"elderly":3},"countries":{"US":71},"first_public_year":"2019","gbp_per_sample_median":7.14,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"colorectal_cancer":12,"other_cancer":59},"intervention_design":"none","intervention_detail":"","interventions":[],"n_samples":71,"papers":[{"doi":"10.1186/s40168-020-00811-2","pmcid":"PMC7059390","pmid":"32138779","title":"Predictable modulation of cancer treatment outcomes by the gut microbiota."},{"doi":"10.1002/advs.202411052","pmcid":"PMC12245021","pmid":"40285661","title":"β-Glucuronidase-Expressing Lactobacillus reuteri Triggers Irinotecan Enterotoxicity Through Depleting the Regenerative Epithelial Stem/Progenitor Pool."},{"doi":"10.1002/cam4.6503","pmcid":"PMC10557844","pmid":"37676050","title":"Identification of microbial markers associated with lung cancer based on multi-cohort 16 s rRNA analyses: A systematic review and meta-analysis."},{"doi":"10.3389/fcimb.2025.1591076","pmcid":"PMC12336193","pmid":"40792105","title":"Exploring fecal microbiota signatures associated with immune response and antibiotic impact in NSCLC: insights from metagenomic and machine learning approaches."},{"doi":"10.34133/csbj.0065","pmcid":"PMC13173278","pmid":"42146906","title":"Ecological and Functional Stratification of the Stool Microbiome Predicts Response to Immune Checkpoint Inhibitors across Cancer Types."}],"sample_intervention_arms":{"drug_therapy":23},"sex":{"female":40,"male":31},"title":"Gut metagenomic raw sequence reads of cancer patients","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA494824","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA494824_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA494824.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA494824.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA494824.csv.gz"}},{"accession":"PRJNA928744","age_categories":{"adult":27,"elderly":44},"countries":{"CA":71},"first_public_year":"2023","gbp_per_sample_median":5.2,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":false,"health_conditions":{"healthy_control":11,"other_cancer":60},"intervention_design":"single_arm_before_after","intervention_detail":"FMT from healthy donor combined with anti-PD1 therapy in melanoma","interventions":["drug_therapy","fmt"],"n_samples":71,"papers":[{"doi":"10.1136/jitc-2025-012659","pmcid":"PMC12359429","pmid":"40759441","title":"Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial."},{"doi":"10.1016/j.chom.2024.10.006","pmcid":"PMC11629153","pmid":"39481388","title":"Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients."},{"doi":"10.1038/s41586-025-09249-8","pmcid":"PMC12390848","pmid":"40659786","title":"Microbiota-driven antitumour immunity mediated by dendritic cell migration."},{"doi":"10.1186/s40168-025-02249-w","pmcid":"PMC12590682","pmid":"41199348","title":"Accurate profiling of microbial communities for shotgun metagenomic sequencing with Meteor2."},{"doi":"10.34133/csbj.0065","pmcid":"PMC13173278","pmid":"42146906","title":"Ecological and Functional Stratification of the Stool Microbiome Predicts Response to Immune Checkpoint Inhibitors across Cancer Types."}],"sample_intervention_arms":{},"sex":{"female":20,"male":40},"title":"Gut microbiota composition of patients in MIMic cohort","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA928744","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA928744_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA928744.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA928744.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA928744.csv.gz"}},{"accession":"PRJNA1226730","age_categories":{"unknown":68},"countries":{"CN":68},"first_public_year":"2026","gbp_per_sample_median":6.65,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":68},"intervention_design":"single_arm_before_after","intervention_detail":"Neoadjuvant tislelizumab (anti-PD-1) plus platinum-based doublet chemotherapy","interventions":["drug_therapy"],"n_samples":68,"papers":[{"doi":"10.1002/ctm2.70579","pmcid":"PMC12778419","pmid":"41499358","title":"Baseline multi-omics signatures could predict therapeutic response to neoadjuvant anti-PD-1 immunochemotherapy in non-small-cell lung cancer."}],"sample_intervention_arms":{},"sex":{},"title":"Gut metagenome_Homo sapiens_PD1 Raw sequence reads","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1226730","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1226730_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1226730.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1226730.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1226730.csv.gz"}},{"accession":"PRJNA579147","age_categories":{"adult":68},"countries":{"US":68},"first_public_year":"2019","gbp_per_sample_median":3.21,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{},"intervention_design":"observational_with_procedure","intervention_detail":"IL-17 inhibitor biologic therapy in spondyloarthritis/psoriatic arthritis","interventions":[],"n_samples":68,"papers":[{"doi":"10.1002/art.41169","pmcid":"PMC7113119","pmid":"31729183","title":"Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation."}],"sample_intervention_arms":{"drug_therapy":39,"no_intervention":29},"sex":{},"title":"Manuscript: IL-17 Inhibition in Spondyloarthritis Associates with Subclinical Gut Microbiome Perturbations and a Distinctive IL-25-Driven Intestinal Inflammation","trial_population_condition":"autoimmune_inflammatory","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA579147","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA579147_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA579147.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA579147.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA579147.csv.gz"}},{"accession":"PRJNA1063508","age_categories":{"adult":66},"countries":{"RU":66},"first_public_year":"2024","gbp_per_sample_median":2.22,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_infection":66},"intervention_design":"randomized_controlled_trial","intervention_detail":"H. pylori eradication: esomeprazole, clarithromycin, amoxicillin, bismuth +/- butyric acid+inulin (Zacofalk)","interventions":["antibiotic","drug_therapy"],"n_samples":66,"papers":[{"doi":"10.3390/microorganisms12020319","pmcid":"PMC10892928","pmid":"38399723","title":"Butyric Acid Supplementation Reduces Changes in the Taxonomic and Functional Composition of Gut Microbiota Caused by H. pylori Eradication Therapy."}],"sample_intervention_arms":{"drug_therapy":33},"sex":{},"title":"Gut microbiota after H. pylori eradication therapy","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1063508","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1063508_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1063508.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1063508.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1063508.csv.gz"}},{"accession":"PRJEB61942","age_categories":{"adult":65},"countries":{"IT":65},"first_public_year":"2024","gbp_per_sample_median":8.2,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":65},"intervention_design":"none","intervention_detail":"","interventions":[],"n_samples":65,"papers":[{"doi":"10.1016/j.chom.2024.10.006","pmcid":"PMC11629153","pmid":"39481388","title":"Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients."}],"sample_intervention_arms":{"drug_therapy":65},"sex":{},"title":"Longitudinal study of the gut microbiota during anti-pd1 immunotherapy in melanoma patients.","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB61942","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB61942_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB61942.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB61942.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB61942.csv.gz"}},{"accession":"PRJNA1050903","age_categories":{"unknown":65},"countries":{},"first_public_year":"2024","gbp_per_sample_median":9.06,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"other_cancer":65},"intervention_design":"single_arm_before_after","intervention_detail":"","interventions":[],"n_samples":65,"papers":[{"doi":"10.20517/mrr.2024.49","pmcid":"PMC11977384","pmid":"40207279","title":"Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin."},{"doi":"10.21203/rs.3.rs-3787741/v1","pmcid":null,"pmid":null,"title":"Profiling the gut and oral microbiota of hormone-receptor positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin"}],"sample_intervention_arms":{"drug_therapy":37,"no_intervention":28},"sex":{"female":65},"title":"Human gut metagenome Raw sequence reads","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1050903","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1050903_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1050903.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1050903.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1050903.csv.gz"}},{"accession":"PRJNA1150764","age_categories":{"adult":62,"elderly":2},"countries":{"CN":64},"first_public_year":"2024","gbp_per_sample_median":0.21,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"cardiometabolic_other":64},"intervention_design":"non_randomized_controlled","intervention_detail":"Naoxintong capsule added to atorvastatin for hyperlipidemia","interventions":["drug_therapy"],"n_samples":64,"papers":[{"doi":"10.1016/j.phymed.2026.157799","pmcid":null,"pmid":"41544465","title":"Gut microbiome-metabolomics integration explores the adjunctive effect of Naoxintong capsule on atorvastatin in ameliorating hyperlipidemia: A randomized controlled pilot study."}],"sample_intervention_arms":{},"sex":{"female":32,"male":32},"title":"Integrated gut microbiome and metabolomics to the effects and mechanisms of the addition of Naoxintong capsule to atorvastatin in the treatment of hyperlipidemia","trial_population_condition":"cardiometabolic_other","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1150764","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1150764_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1150764.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1150764.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1150764.csv.gz"}},{"accession":"PRJNA432958","age_categories":{"adult":64},"countries":{"US":64},"first_public_year":"2018","gbp_per_sample_median":8.47,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"healthy_control":64},"intervention_design":"single_arm_before_after","intervention_detail":"Obeticholic acid (FXR agonist) treatment, before/after","interventions":["drug_therapy"],"n_samples":64,"papers":[{"doi":"10.1053/j.gastro.2018.08.022","pmcid":"PMC6279623","pmid":"30144429","title":"FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid."}],"sample_intervention_arms":{"drug_therapy":64},"sex":{},"title":"FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid","trial_population_condition":"healthy_control","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA432958","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA432958_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA432958.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA432958.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA432958.csv.gz"}},{"accession":"PRJEB110927","age_categories":{"adult":35,"elderly":18,"unknown":8},"countries":{"FR":61},"first_public_year":"2026","gbp_per_sample_median":6.83,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"randomized_controlled_trial","intervention_detail":"FOLFIRI + durvalumab with or without tremelimumab","interventions":["drug_therapy"],"n_samples":61,"papers":[{"doi":"10.1053/j.gastro.2024.10.020","pmcid":null,"pmid":"39454892","title":"Faecalibacteriumprausnitzii Is Associated With Clinical Response to Immune Checkpoint Inhibitors in Patients With Advanced Gastric Adenocarcinoma: Results of Microbiota Analysis of PRODIGE 59-FFCD 170"}],"sample_intervention_arms":{},"sex":{"female":22,"male":34},"title":"Durigast_F_prausnitzii_ICI_gastric_adenocarcinoma","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB110927","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB110927_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB110927.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB110927.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB110927.csv.gz"}},{"accession":"PRJNA1042648","age_categories":{"unknown":60},"countries":{"FR":60},"first_public_year":"2024","gbp_per_sample_median":3.11,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":60},"intervention_design":"observational_with_procedure","intervention_detail":"Immune checkpoint blockers and/or chemotherapy for NSCLC","interventions":["drug_therapy"],"n_samples":60,"papers":[],"sample_intervention_arms":{},"sex":{},"title":"Metabolic tumor burden assessed by [18F] FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates: a multicentric study.","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1042648","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1042648_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1042648.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1042648.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1042648.csv.gz"}},{"accession":"PRJNA1468465","age_categories":{"unknown":59},"countries":{"KR":59},"first_public_year":"2026","gbp_per_sample_median":4.63,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"colorectal_cancer":59},"intervention_design":"single_arm_before_after","intervention_detail":"Neoadjuvant atezolizumab + bevacizumab + FOLFOX (ABFOLFOX)","interventions":["drug_therapy"],"n_samples":59,"papers":[{"doi":"10.1186/s13073-026-01680-4","pmcid":"PMC13439765","pmid":"42218533","title":"Dynamics of tumor ecosystems and microbiome in response to neoadjuvant ABFOLFOX treatment in patients with unresectable colorectal cancer with liver metastasis."}],"sample_intervention_arms":{},"sex":{},"title":"Metagenomic profiling of patients with unresectable colorectal cancer liver metastases treated with neoadjuvant atezolizumab and ABFOLFOX","trial_population_condition":"colorectal_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1468465","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1468465_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1468465.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1468465.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1468465.csv.gz"}},{"accession":"PRJNA819232","age_categories":{"unknown":59},"countries":{"ES":55},"first_public_year":"2022","gbp_per_sample_median":1.67,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":true,"health_conditions":{"healthy_control":26,"other_infection":29},"intervention_design":"observational_with_procedure","intervention_detail":"","interventions":[],"n_samples":59,"papers":[{"doi":"10.1007/s40121-022-00654-4","pmcid":"PMC9334516","pmid":"35618952","title":"Integrase Inhibitors Partially Restore Bacterial Translocation, Inflammation and Gut Permeability Induced by HIV Infection: Impact on Gut Microbiota."}],"sample_intervention_arms":{"drug_therapy":15,"no_intervention":44},"sex":{},"title":"Impact of Integrase Inhibitors on gut and oral microbiome","trial_population_condition":"other_infection","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA819232","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA819232_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA819232.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA819232.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA819232.csv.gz"}},{"accession":"PRJEB84128","age_categories":{"adult":57},"countries":{"ES":57},"first_public_year":"2025","gbp_per_sample_median":2.59,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"observational_with_procedure","intervention_detail":"Androgen receptor pathway inhibitor (ARPI) therapy for metastatic prostate cancer","interventions":["drug_therapy"],"n_samples":57,"papers":[{"doi":"10.21203/rs.3.rs-5837549/v1","pmcid":null,"pmid":null,"title":"Gut microbiota metabolic reprogramming in metastatic prostatic cancer: prognostic value in patients under androgen receptor pathway inhibitors therapy."}],"sample_intervention_arms":{},"sex":{},"title":"Gut microbiota signatures associated with advanced metastatic prostatic cancer treated with androgen receptor pathway inhibitor therapy","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB84128","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB84128_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB84128.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB84128.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB84128.csv.gz"}},{"accession":"PRJNA1254622","age_categories":{"adult":57},"countries":{"HU":57},"first_public_year":"2026","gbp_per_sample_median":6.87,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":true,"health_conditions":{"colorectal_cancer":39,"healthy_control":18},"intervention_design":"unknown","intervention_detail":"","interventions":[],"n_samples":57,"papers":[{"doi":"10.20944/preprints202606.0192.v1","pmcid":null,"pmid":null,"title":"Baseline Gut Microbiome Profiling in Therapy-Naive Patients with Locally Advanced Rectal Cancer Identifies Signatures of Response to Total Neoadjuvant Therapy"}],"sample_intervention_arms":{"drug_therapy":39,"no_intervention":18},"sex":{},"title":"Patients with pelvic irradiation","trial_population_condition":"colorectal_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1254622","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1254622_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1254622.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1254622.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1254622.csv.gz"}},{"accession":"PRJNA1065951","age_categories":{"adult":56},"countries":{"CN":56},"first_public_year":"2024","gbp_per_sample_median":12.58,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"colorectal_cancer":7,"other_disease":35},"intervention_design":"single_arm_before_after","intervention_detail":"FMT capsules from healthy donors combined with nivolumab (anti-PD-1)","interventions":["drug_therapy","fmt"],"n_samples":56,"papers":[{"doi":"10.1136/jitc-2025-013823","pmcid":"PMC13034380","pmid":"41871875","title":"Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study."}],"sample_intervention_arms":{"fmt":46,"no_intervention":10},"sex":{},"title":"Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients","trial_population_condition":"colorectal_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1065951","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1065951_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1065951.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1065951.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1065951.csv.gz"}},{"accession":"PRJEB98485","age_categories":{"adult":36,"elderly":19},"countries":{"LV":55},"first_public_year":"2025","gbp_per_sample_median":6.96,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":true,"health_conditions":{"healthy_control":36,"neurological_psychiatric":4,"other_disease":15},"intervention_design":"none","intervention_detail":"","interventions":[],"n_samples":55,"papers":[],"sample_intervention_arms":{"drug_therapy":12,"no_intervention":6},"sex":{"female":44,"male":11},"title":"Shotgun metagenomic sequencing of the gut microbiome reveals hormone‐specific taxonomic and functional shifts in PitNET patients","trial_population_condition":"other_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB98485","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB98485_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB98485.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB98485.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB98485.csv.gz"}},{"accession":"PRJNA1104421","age_categories":{"adult":54},"countries":{"FR":54},"first_public_year":"2024","gbp_per_sample_median":1.85,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"liver_disease":54},"intervention_design":"single_arm_before_after","intervention_detail":"7-day corticosteroid (prednisolone) therapy in severe alcoholic hepatitis","interventions":["drug_therapy"],"n_samples":54,"papers":[{"doi":"10.1080/19490976.2024.2382767","pmcid":"PMC11290774","pmid":"39078043","title":"Serum bile acids profiles are altered without change of the gut microbiota composition following a seven-day prednisolone therapy in severe alcoholic hepatitis."}],"sample_intervention_arms":{"drug_therapy":27,"no_intervention":27},"sex":{},"title":"Serum Bile Acids profiles are altered without change of the Gut Microbiota composition following a seven-day prednisolone therapy in severe alcoholic hepatitis","trial_population_condition":"liver_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1104421","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1104421_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1104421.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1104421.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1104421.csv.gz"}},{"accession":"PRJNA720145","age_categories":{"adult":54},"countries":{"US":54},"first_public_year":"2021","gbp_per_sample_median":5.19,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"observational_with_procedure","intervention_detail":"Oral fluoropyrimidine (capecitabine/TAS-102) +/- pembrolizumab/bevacizumab chemotherapy","interventions":["drug_therapy"],"n_samples":54,"papers":[{"doi":"10.1038/s41564-022-01226-5","pmcid":"PMC9530025","pmid":"36138165","title":"Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism."}],"sample_intervention_arms":{"no_intervention":10},"sex":{},"title":"GO: Gut Microbiome and Oral Fluoropyrimidine Study in Patients with Colorectal Cancer","trial_population_condition":"colorectal_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA720145","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA720145_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA720145.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA720145.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA720145.csv.gz"}},{"accession":"PRJEB78503","age_categories":{"unknown":52},"countries":{"FR":52},"first_public_year":"2025","gbp_per_sample_median":24.54,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":52},"intervention_design":"single_arm_before_after","intervention_detail":"High-dose methotrexate-based polychemotherapy, samples before/after therapy","interventions":["drug_therapy"],"n_samples":52,"papers":[{"doi":"10.1093/neuonc/noaf059","pmcid":"PMC12448904","pmid":"40048707","title":"Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: An ancillary study from the BLOCAGE trial."}],"sample_intervention_arms":{},"sex":{},"title":"Gut microbiome study on Primary central nervous system lymphoma (PCNSL) demonstrates that chemotherapy response modulation is driven by specific microorganisms through the gut-brain axis.","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB78503","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB78503_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB78503.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB78503.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB78503.csv.gz"}},{"accession":"PRJNA1130699","age_categories":{"adult":19,"elderly":32},"countries":{"KR":51},"first_public_year":"2024","gbp_per_sample_median":17.72,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":51},"intervention_design":"observational_with_procedure","intervention_detail":"Anti-PD-L1/anti-PD-1 immune checkpoint blockade therapy","interventions":["drug_therapy"],"n_samples":51,"papers":[{"doi":"10.1038/s41467-024-55388-3","pmcid":"PMC11680825","pmid":"39730328","title":"A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy."}],"sample_intervention_arms":{"drug_therapy":51},"sex":{"female":12,"male":39},"title":"Whole metagenomic shotgun sequencing on fecal samples of NSCLC patients who received ICB treatment","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1130699","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1130699_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1130699.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1130699.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1130699.csv.gz"}},{"accession":"PRJEB85676","age_categories":{"adult":48},"countries":{"FR":48},"first_public_year":"2025","gbp_per_sample_median":3.0,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":48},"intervention_design":"single_arm_before_after","intervention_detail":"Low-dose intestinal irradiation + PD-L1 blockade, phase 2 trial","interventions":["drug_therapy","other_intervention"],"n_samples":48,"papers":[{"doi":"10.1016/j.ccell.2025.02.010","pmcid":"PMC11907695","pmid":"40068595","title":"Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients."}],"sample_intervention_arms":{},"sex":{},"title":"Low-Dose Irradiation of the Gut Improves the Efficacy of PD-L1 Blockade in Metastatic Cancer Patients","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB85676","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB85676_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB85676.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB85676.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB85676.csv.gz"}},{"accession":"PRJNA1281554","age_categories":{"adolescent":48},"countries":{"US":48},"first_public_year":"2025","gbp_per_sample_median":1.4,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"type2_diabetes":48},"intervention_design":"randomized_controlled_trial","intervention_detail":"Randomized to metformin alone vs metformin+liraglutide for 3 months","interventions":["drug_therapy"],"n_samples":48,"papers":[{"doi":"10.1080/19490976.2025.2558071","pmcid":"PMC12482426","pmid":"41020378","title":"Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study."}],"sample_intervention_arms":{},"sex":{},"title":"Targeting the Gut Microbiome in Youth-Onset Type 2 Diabetes: Effects of Metformin and Liraglutide Therapy","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1281554","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1281554_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1281554.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1281554.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1281554.csv.gz"}},{"accession":"PRJNA541981","age_categories":{"adult":15,"elderly":33},"countries":{"US":48},"first_public_year":"2019","gbp_per_sample_median":4.59,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":48},"intervention_design":"none","intervention_detail":"","interventions":[],"n_samples":48,"papers":[{"doi":"10.1186/s13073-019-0672-4","pmcid":"PMC6785875","pmid":"31597568","title":"Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients."},{"doi":"10.1186/s13073-021-00974-z","pmcid":"PMC8513370","pmid":"34641962","title":"Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma."},{"doi":"10.1084/jem.20200606","pmcid":"PMC7664509","pmid":"33175106","title":"Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers."},{"doi":"10.1172/jci.insight.140940","pmcid":"PMC7714408","pmid":"33268597","title":"Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma."},{"doi":"10.1158/1078-0432.ccr-20-4834","pmcid":"PMC9053858","pmid":"33593881","title":"A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors."}],"sample_intervention_arms":{"drug_therapy":48},"sex":{"female":6,"male":42},"title":"Gut microbiome in melanoma patients","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA541981","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA541981_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA541981.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA541981.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA541981.csv.gz"}},{"accession":"PRJNA808806","age_categories":{"adult":48},"countries":{"CN":48},"first_public_year":"2023","gbp_per_sample_median":7.1,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"healthy_control":12},"intervention_design":"observational_with_procedure","intervention_detail":"","interventions":[],"n_samples":48,"papers":[{"doi":"10.3389/fmicb.2023.1283276","pmcid":"PMC10635210","pmid":"37954240","title":"Methadone maintenance treatment is more effective than compulsory detoxification in addressing gut microbiota dysbiosis caused by heroin abuse."}],"sample_intervention_arms":{"drug_therapy":12},"sex":{"male":48},"title":"human gut metagenome Raw sequence reads","trial_population_condition":"other_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA808806","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA808806_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA808806.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA808806.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA808806.csv.gz"}},{"accession":"PRJEB46214","age_categories":{"unknown":47},"countries":{"CA":47},"first_public_year":"2021","gbp_per_sample_median":1.0,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":47},"intervention_design":"single_arm_before_after","intervention_detail":"Pegaspargase chemotherapy treatment in pediatric ALL patients, sampled over treatment","interventions":["drug_therapy"],"n_samples":47,"papers":[{"doi":"10.1080/10428194.2021.1953006","pmcid":null,"pmid":"34279176","title":"Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia."},{"doi":"10.3389/fcimb.2022.924707","pmcid":"PMC9363618","pmid":"35967843","title":"Antibiotic and antifungal use in pediatric leukemia and lymphoma patients are associated with increasing opportunistic pathogens and decreasing bacteria responsible for activities that enhance colonic"},{"doi":"10.3389/fcimb.2023.1102501","pmcid":"PMC9998685","pmid":"36909730","title":"The gastrointestinal antibiotic resistome in pediatric leukemia and lymphoma patients."}],"sample_intervention_arms":{},"sex":{},"title":"Gut bacterial gene changes following pegaspargase treatment in pediatric patients with Acute Lymphoblastic Leukemia","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB46214","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB46214_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB46214.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB46214.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB46214.csv.gz"}},{"accession":"PRJNA1054290","age_categories":{"unknown":44},"countries":{"CN":44},"first_public_year":"2025","gbp_per_sample_median":6.4,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"colorectal_cancer":44},"intervention_design":"single_arm_before_after","intervention_detail":"Adjuvant chemoradiotherapy and immunotherapy in CRC patients, sampled before/after","interventions":["drug_therapy"],"n_samples":44,"papers":[],"sample_intervention_arms":{},"sex":{},"title":"metagenomic shotgun sequencing of baseline colorectal cancer patient","trial_population_condition":"colorectal_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1054290","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1054290_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1054290.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1054290.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1054290.csv.gz"}},{"accession":"PRJNA302832","age_categories":{"unknown":44},"countries":{"US":44},"first_public_year":"2015","gbp_per_sample_median":0.56,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":44},"intervention_design":"observational_with_procedure","intervention_detail":"Ipilimumab (CTLA-4 blockade) immunotherapy in melanoma patients","interventions":["drug_therapy"],"n_samples":44,"papers":[{"doi":"10.1371/journal.pone.0198773","pmcid":"PMC6002052","pmid":"29902201","title":"When old metagenomic data meet newly sequenced genomes, a case study."},{"doi":"10.1186/s13073-024-01285-9","pmcid":"PMC10799412","pmid":"38243343","title":"Gut microbiome for predicting immune checkpoint blockade-associated adverse events."},{"doi":"10.1038/ncomms10391","pmcid":"PMC4740747","pmid":"26837003","title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis."}],"sample_intervention_arms":{},"sex":{},"title":"Human gut Metagenome","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA302832","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA302832_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA302832.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA302832.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA302832.csv.gz"}},{"accession":"PRJNA397906","age_categories":{"adult":17,"elderly":22,"unknown":5},"countries":{"US":44},"first_public_year":"2017","gbp_per_sample_median":9.06,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":44},"intervention_design":"observational_with_procedure","intervention_detail":"Immune checkpoint inhibitor therapy in melanoma patients","interventions":["drug_therapy"],"n_samples":44,"papers":[{"doi":"10.1016/j.neo.2017.08.004","pmcid":"PMC5602478","pmid":"28923537","title":"Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients."},{"doi":"10.1093/g3journal/jkab046","pmcid":"PMC8049424","pmid":"33713107","title":"MetaPrism: A versatile toolkit for joint taxa/gene analysis of metagenomic sequencing data."},{"doi":"10.1016/j.xpro.2024.102847","pmcid":"PMC10837094","pmid":"38277270","title":"Protocol to identify fungal profile from fecal metagenomes in cancer patients prior to immunotherapy."},{"doi":"10.1016/j.slast.2025.100365","pmcid":null,"pmid":"41241214","title":"Technology-enabled integration of single-cell transcriptomics and microbiome data identifies RNA-targetable host-microbiota networks in colorectal adenoma."},{"doi":"10.1084/jem.20200606","pmcid":"PMC7664509","pmid":"33175106","title":"Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers."}],"sample_intervention_arms":{},"sex":{"female":9,"male":30},"title":"Metagenomic shotgun sequencing of gut microbiomes of melanoma patients receiving immune checkpoint inhibitor therapy","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA397906","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA397906_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA397906.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA397906.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA397906.csv.gz"}},{"accession":"PRJNA486795","age_categories":{"adult":44},"countries":{"CN":44},"first_public_year":"2018","gbp_per_sample_median":8.97,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{},"intervention_design":"single_arm_before_after","intervention_detail":"Metformin 3-day treatment in newly diagnosed T2D patients","interventions":["drug_therapy"],"n_samples":44,"papers":[{"doi":"10.1038/s41591-018-0222-4","pmcid":"PMC6479226","pmid":"30397356","title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin."},{"doi":"10.1371/journal.pone.0242021","pmcid":"PMC7707550","pmid":"33259474","title":"Perturbation of the human gastrointestinal tract microbial ecosystem by oral drugs to treat chronic disease results in a spectrum of individual specific patterns of extinction and persistence of domin"},{"doi":"10.1128/mbio.00169-24","pmcid":"PMC11237675","pmid":"38767350","title":"Changes in the type 2 diabetes gut mycobiome associate with metformin treatment across populations."}],"sample_intervention_arms":{"drug_therapy":22,"no_intervention":22},"sex":{},"title":"Modification of gut microbiota-bile acid-intestinal FXR signaling leads to the clinical benefits of metformin","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA486795","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA486795_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA486795.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA486795.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA486795.csv.gz"}},{"accession":"PRJNA678737","age_categories":{"unknown":42},"countries":{"IL":42},"first_public_year":"2021","gbp_per_sample_median":4.73,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":23},"intervention_design":"single_arm_before_after","intervention_detail":"FMT with anti-PD-1 re-induction in refractory metastatic melanoma, phase I trial","interventions":["fmt"],"n_samples":42,"papers":[{"doi":"10.1186/s12866-021-02312-0","pmcid":"PMC8454007","pmid":"34544375","title":"Incongruence between dominant commensal donor microbes in recipient feces post fecal transplant and response to anti-PD-1 immunotherapy."},{"doi":"10.1126/science.aaz7015","pmcid":"PMC8970537","pmid":"34941392","title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response."},{"doi":"10.1128/msystems.01023-22","pmcid":"PMC10134792","pmid":"36809182","title":"Consistent Stool Metagenomic Biomarkers Associated with the Response To Melanoma Immunotherapy."},{"doi":"10.1038/s41522-023-00421-4","pmcid":"PMC10400536","pmid":"37537181","title":"Donor-recipient specificity and age-dependency in fecal microbiota therapy and probiotic resolution of gastrointestinal symptoms."},{"doi":"10.1186/s13073-024-01285-9","pmcid":"PMC10799412","pmid":"38243343","title":"Gut microbiome for predicting immune checkpoint blockade-associated adverse events."}],"sample_intervention_arms":{"drug_therapy":23},"sex":{},"title":"Fecal microbiota transplantation modulates immunotherapy response in refractory metastatic melanoma patients","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA678737","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA678737_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA678737.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA678737.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA678737.csv.gz"}},{"accession":"PRJNA767599","age_categories":{"unknown":39},"countries":{"LA":39},"first_public_year":"2022","gbp_per_sample_median":1.06,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"gi_infection_or_diarrhoea":39},"intervention_design":"randomized_controlled_trial","intervention_detail":"Albendazole alone vs albendazole-ivermectin combination therapy for helminth infection","interventions":["drug_therapy"],"n_samples":39,"papers":[{"doi":"10.1038/s41467-022-28658-1","pmcid":"PMC8881608","pmid":"35217670","title":"Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases."}],"sample_intervention_arms":{"drug_therapy":39},"sex":{},"title":"Gut microbial communities modulate efficacy of albendazole-ivermectin against soil-transmitted helminthiases","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA767599","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA767599_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA767599.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA767599.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA767599.csv.gz"}},{"accession":"PRJNA1289810","age_categories":{"adult":38},"countries":{"US":38},"first_public_year":"2025","gbp_per_sample_median":3.28,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"other_infection":38},"intervention_design":"single_arm_before_after","intervention_detail":"N-803 (IL-15 superagonist) immunotherapy in HIV patients","interventions":["drug_therapy"],"n_samples":38,"papers":[{"doi":"10.1093/cid/ciag369","pmcid":null,"pmid":"42402338","title":"Pre-treatment Gut Microbiome Diversity and Function Linked to Cytotoxic and Natural Killer Cell Immune Responses after N-803 Treatment in People with HIV."},{"doi":"10.1101/2025.10.01.679827","pmcid":null,"pmid":null,"title":"Pre-treatment Microbiome Diversity and Function is associated with Expansion of Cytotoxic and Regulatory Immune Populations after N-803 treatment in People with HIV"}],"sample_intervention_arms":{"drug_therapy":28,"no_intervention":10},"sex":{},"title":"Baseline Gut Microbiome Diversity Correlates with Immune Responses in People with HIV Receiving N-803","trial_population_condition":"other_infection","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1289810","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1289810_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1289810.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1289810.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1289810.csv.gz"}},{"accession":"PRJNA929558","age_categories":{"adult":30,"elderly":8},"countries":{"US":38},"first_public_year":"2023","gbp_per_sample_median":0.42,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"autoimmune_inflammatory":38},"intervention_design":"single_arm_before_after","intervention_detail":"Sulfasalazine therapy in IBD-associated pSpA subjects","interventions":["drug_therapy"],"n_samples":38,"papers":[{"doi":"10.1016/j.xcrm.2024.101431","pmcid":"PMC10982976","pmid":"38378002","title":"The gut microbiome regulates the clinical efficacy of sulfasalazine therapy for IBD-associated spondyloarthritis."}],"sample_intervention_arms":{},"sex":{"female":20,"male":18},"title":"Sulfasalazine therapy for IBD-associated pSpA","trial_population_condition":"autoimmune_inflammatory","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA929558","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA929558_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA929558.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA929558.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA929558.csv.gz"}},{"accession":"PRJEB58222","age_categories":{"adult":37},"countries":{"DE":37},"first_public_year":"2023","gbp_per_sample_median":9.63,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":37},"intervention_design":"unknown","intervention_detail":"FMT, tryptophan diet manipulation, oral 3-IAA, chemotherapy in mouse models; human cohorts observed","interventions":["diet_intervention","dietary_supplement","drug_therapy","fmt"],"n_samples":37,"papers":[{"doi":"10.1038/s41586-023-05728-y","pmcid":"PMC9977685","pmid":"36813961","title":"Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer."}],"sample_intervention_arms":{},"sex":{},"title":"Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB58222","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB58222_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB58222.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB58222.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB58222.csv.gz"}},{"accession":"PRJNA1238196","age_categories":{"unknown":36},"countries":{},"first_public_year":"2025","gbp_per_sample_median":6.02,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"type2_diabetes":36},"intervention_design":"single_arm_before_after","intervention_detail":"Dapagliflozin (SGLT2i) 10mg/day, 8 weeks","interventions":["drug_therapy"],"n_samples":36,"papers":[{"doi":"10.3389/fphar.2025.1600464","pmcid":"PMC12095364","pmid":"40406484","title":"Reduced abundance of <i>Fusobacterium</i> signifies cardiovascular benefits of sodium glucose cotransporter 2 inhibitor in type 2 diabetes: a single arm clinical trial."}],"sample_intervention_arms":{},"sex":{},"title":"Fecal samples from T2DM patients","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1238196","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1238196_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1238196.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1238196.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1238196.csv.gz"}},{"accession":"PRJNA997572","age_categories":{"unknown":36},"countries":{"CN":36},"first_public_year":"2025","gbp_per_sample_median":6.43,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"type2_diabetes":36},"intervention_design":"single_arm_before_after","intervention_detail":"Metformin treatment in newly diagnosed T2DM patients","interventions":["drug_therapy"],"n_samples":36,"papers":[],"sample_intervention_arms":{},"sex":{},"title":"Research on the Mechanism of Metformin Improving Type 2 Diabetes","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA997572","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA997572_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA997572.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA997572.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA997572.csv.gz"}},{"accession":"PRJNA750475","age_categories":{"adult":35},"countries":{"US":35},"first_public_year":"2021","gbp_per_sample_median":3.24,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"healthy_control":35},"intervention_design":"single_arm_before_after","intervention_detail":"Oral contraceptive use, sampled baseline, 1 and 6 months after","interventions":["drug_therapy"],"n_samples":35,"papers":[{"doi":"10.1099/jmm.0.001512","pmcid":null,"pmid":"35452382","title":"Longitudinal analysis of the impact of oral contraceptive use on the gut microbiome."}],"sample_intervention_arms":{"drug_therapy":22,"no_intervention":13},"sex":{},"title":"Longitudinal Analysis of Gut Microbiome among healthy women","trial_population_condition":"healthy_control","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA750475","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA750475_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA750475.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA750475.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA750475.csv.gz"}},{"accession":"PRJNA656577","age_categories":{"adult":32,"elderly":2},"countries":{"US":34},"first_public_year":"2021","gbp_per_sample_median":4.55,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"autoimmune_inflammatory":34},"intervention_design":"single_arm_before_after","intervention_detail":"Methotrexate treatment in RA patients, pre- vs post-treatment microbiota","interventions":["drug_therapy"],"n_samples":34,"papers":[{"doi":"10.1016/j.chom.2020.12.008","pmcid":"PMC7954989","pmid":"33440172","title":"Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation."}],"sample_intervention_arms":{"drug_therapy":17,"no_intervention":17},"sex":{"female":24,"male":10},"title":"Effect of methotrexate on human gut microbiota","trial_population_condition":"autoimmune_inflammatory","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA656577","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA656577_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA656577.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA656577.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA656577.csv.gz"}},{"accession":"PRJEB51010","age_categories":{"adult":33},"countries":{},"first_public_year":"2022","gbp_per_sample_median":6.76,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"type2_diabetes":33},"intervention_design":"single_arm_before_after","intervention_detail":"Duodenal mucosal resurfacing ablation + GLP-1 receptor agonist in T2DM","interventions":["drug_therapy","surgery"],"n_samples":33,"papers":[{"doi":"10.3389/fcdhc.2022.856661","pmcid":"PMC10012157","pmid":"36992788","title":"A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study."}],"sample_intervention_arms":{},"sex":{},"title":"The effect of intestinal ablation on the microbiome","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB51010","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB51010_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB51010.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB51010.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB51010.csv.gz"}},{"accession":"PRJNA1469454","age_categories":{"adult":24,"elderly":8},"countries":{"RU":32},"first_public_year":"2026","gbp_per_sample_median":4.44,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":32},"intervention_design":"unknown","intervention_detail":"Immune checkpoint inhibitor immunotherapy, pre- vs 3-month post-treatment","interventions":["drug_therapy"],"n_samples":32,"papers":[],"sample_intervention_arms":{},"sex":{"female":18,"male":14},"title":"Human gut metagenome from melanoma patients collected at two timepoints","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1469454","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1469454_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1469454.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1469454.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1469454.csv.gz"}},{"accession":"PRJNA1011235","age_categories":{"adult":29},"countries":{"DE":29},"first_public_year":"2023","gbp_per_sample_median":8.24,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":29},"intervention_design":"observational_with_procedure","intervention_detail":"Checkpoint inhibitor (anti-PD-1/anti-CTLA-4) therapy in melanoma patients","interventions":["drug_therapy"],"n_samples":29,"papers":[{"doi":"10.1186/s12885-023-11551-5","pmcid":"PMC10685659","pmid":"38017389","title":"TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients."},{"doi":"10.34133/csbj.0065","pmcid":"PMC13173278","pmid":"42146906","title":"Ecological and Functional Stratification of the Stool Microbiome Predicts Response to Immune Checkpoint Inhibitors across Cancer Types."},{"doi":"10.1080/19490976.2026.2681788","pmcid":"PMC13274128","pmid":"42298353","title":"Gut microbial markers of immunotherapy response in melanoma: a cross-cohort analysis including the first Russian dataset."}],"sample_intervention_arms":{},"sex":{},"title":"ANIMA","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1011235","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1011235_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1011235.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1011235.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1011235.csv.gz"}},{"accession":"PRJNA658422","age_categories":{"adolescent":11,"child":18},"countries":{"CN":29},"first_public_year":"2020","gbp_per_sample_median":7.29,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":true,"health_conditions":{"autoimmune_inflammatory":20,"healthy_control":9},"intervention_design":"single_arm_before_after","intervention_detail":"Multi-drug therapy for IgA vasculitis, before/after","interventions":["drug_therapy"],"n_samples":29,"papers":[{"doi":"10.1002/cti2.1342","pmcid":"PMC8499602","pmid":"34646556","title":"Metagenomic profiling reveals dominance of gram-positive bacteria in the gut microbiome shifts associated with immunoglobulin A vasculitis (Henoch-Schönlein Purpura)."}],"sample_intervention_arms":{"drug_therapy":10,"no_intervention":19},"sex":{"female":13,"male":16},"title":"gut microbiome shifts associated with Henoch-Schonlein purpura","trial_population_condition":"autoimmune_inflammatory","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA658422","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA658422_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA658422.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA658422.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA658422.csv.gz"}},{"accession":"PRJEB31790","age_categories":{"adult":28},"countries":{"US":28},"first_public_year":"2019","gbp_per_sample_median":7.29,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"healthy_control":28},"intervention_design":"observational_with_procedure","intervention_detail":"Ex vivo gut community incubation with dexamethasone, diltiazem, famciclovir, norethindrone acetate","interventions":["drug_therapy"],"n_samples":28,"papers":[{"doi":"10.1038/s41586-019-1291-3","pmcid":"PMC6597290","pmid":"31158845","title":"Mapping human microbiome drug metabolism by gut bacteria and their genes."},{"doi":"10.1038/s41586-025-09273-8","pmcid":"PMC13092348","pmid":"40670788","title":"Identification of medication-microbiome interactions that affect gut infection."},{"doi":"10.7554/elife.82401","pmcid":"PMC10289814","pmid":"37306300","title":"SIMMER employs similarity algorithms to accurately identify human gut microbiome species and enzymes capable of known chemical transformations."},{"doi":"10.1016/j.chom.2025.07.008","pmcid":"PMC12683948","pmid":"40763732","title":"Metabolic cross-feeding of a dietary antioxidant enhances anaerobic energy metabolism by human gut bacteria."}],"sample_intervention_arms":{},"sex":{"female":10,"male":18},"title":"Drug metabolism by 28 human gut communities","trial_population_condition":"healthy_control","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB31790","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB31790_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB31790.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB31790.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB31790.csv.gz"}},{"accession":"PRJNA1130508","age_categories":{"adult":27},"countries":{"US":27},"first_public_year":"2024","gbp_per_sample_median":7.16,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"single_arm_before_after","intervention_detail":"Exogenous testosterone for gender-affirming hormone therapy, sampled before and up to 8 months after","interventions":["drug_therapy"],"n_samples":27,"papers":[{"doi":"10.1128/msphere.00557-24","pmcid":"PMC11520287","pmid":"39254049","title":"Testosterone treatment impacts the intestinal microbiome of transgender individuals."}],"sample_intervention_arms":{},"sex":{},"title":"The microbiome of men on gender-affirming hormone therapy","trial_population_condition":"other_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1130508","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1130508_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1130508.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1130508.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1130508.csv.gz"}},{"accession":"PRJNA910923","age_categories":{"adult":26},"countries":{"CN":26},"first_public_year":"2023","gbp_per_sample_median":10.72,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"type2_diabetes":26},"intervention_design":"single_arm_before_after","intervention_detail":"Metformin treatment 3-6 months in T2D patients","interventions":["drug_therapy"],"n_samples":26,"papers":[{"doi":"10.1038/s41522-023-00419-y","pmcid":"PMC10366088","pmid":"37488134","title":"Bacteroides ovatus accelerates metformin-induced vitamin B12 deficiency in type 2 diabetes patients by accumulating cobalamin."}],"sample_intervention_arms":{"drug_therapy":26},"sex":{"female":10,"male":16},"title":"Gut microbiota accelerate metformin-induced vitamin B12 deficiency","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA910923","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA910923_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA910923.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA910923.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA910923.csv.gz"}},{"accession":"PRJNA1200201","age_categories":{"unknown":24},"countries":{"CN":24},"first_public_year":"2025","gbp_per_sample_median":6.65,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":true,"health_conditions":{"healthy_control":6,"transplant_or_immunocompromised":18},"intervention_design":"observational_with_procedure","intervention_detail":"Liver transplant recipients, tacrolimus dosage groups observed (not assigned)","interventions":["surgery"],"n_samples":24,"papers":[{"doi":"10.3389/fmicb.2025.1616985","pmcid":"PMC12498155","pmid":"41059058","title":"Influence of the gut microbiota on the pharmacokinetics of tacrolimus in liver transplant recipients: insights from microbiome analysis."}],"sample_intervention_arms":{"drug_therapy":18,"no_intervention":6},"sex":{},"title":"Relationship between oral tacrolimus and intestinal microecology after liver transplantation","trial_population_condition":"transplant_or_immunocompromised","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1200201","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1200201_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1200201.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1200201.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1200201.csv.gz"}},{"accession":"PRJNA407815","age_categories":{"unknown":24},"countries":{"ID":20,"LR":4},"first_public_year":"2017","gbp_per_sample_median":15.89,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"gi_infection_or_diarrhoea":19},"intervention_design":"unknown","intervention_detail":"","interventions":[],"n_samples":24,"papers":[{"doi":"10.1186/s40168-018-0416-5","pmcid":"PMC6389212","pmid":"29486796","title":"Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia."},{"doi":"10.1186/s40168-020-00894-x","pmcid":"PMC7409454","pmid":"32753050","title":"The human gut archaeome: identification of diverse haloarchaea in Korean subjects."},{"doi":"10.1016/j.immuni.2022.04.001","pmcid":"PMC9123649","pmid":"35483356","title":"Tissue remodeling by an opportunistic pathogen triggers allergic inflammation."}],"sample_intervention_arms":{"drug_therapy":10,"placebo":10},"sex":{},"title":"Microbiome and Worm Infection","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA407815","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA407815_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA407815.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA407815.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA407815.csv.gz"}},{"accession":"PRJNA1222800","age_categories":{"adult":13,"elderly":10},"countries":{"US":23},"first_public_year":"2025","gbp_per_sample_median":14.36,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":23},"intervention_design":"single_arm_before_after","intervention_detail":"Nivolumab plus low-dose ipilimumab, phase II trial, 2 years","interventions":["drug_therapy"],"n_samples":23,"papers":[{"doi":"10.1038/s41467-025-59695-1","pmcid":"PMC12075640","pmid":"40360544","title":"Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)."}],"sample_intervention_arms":{},"sex":{"female":23},"title":"Fecal metagenomes from patients with HER2-negative metastatic breast cancer","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1222800","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1222800_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1222800.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1222800.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1222800.csv.gz"}},{"accession":"PRJNA629392","age_categories":{"adolescent":6,"child":12,"infant":3},"countries":{"TR":21},"first_public_year":"2020","gbp_per_sample_median":3.4,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"autoimmune_inflammatory":21},"intervention_design":"single_arm_before_after","intervention_detail":"Eculizumab (C5 inhibitor) therapy in CHAPLE disease, 14 months","interventions":["drug_therapy"],"n_samples":21,"papers":[{"doi":"10.1038/s41522-023-00392-6","pmcid":"PMC10175488","pmid":"37169786","title":"Comprehensive insights from composition to functional microbe-based biodiversity of the infant human gut microbiota."}],"sample_intervention_arms":{"drug_therapy":21},"sex":{"female":9,"male":12},"title":"Metabolic recovery with eculizumab precision therapy of CHAPLE disease","trial_population_condition":"autoimmune_inflammatory","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA629392","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA629392_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA629392.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA629392.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA629392.csv.gz"}},{"accession":"PRJNA1050658","age_categories":{"unknown":20},"countries":{"CN":20},"first_public_year":"2024","gbp_per_sample_median":6.58,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":20},"intervention_design":"single_arm_before_after","intervention_detail":"Chemotherapy and antibiotics in acute leukemia, pre/post sampling","interventions":["drug_therapy"],"n_samples":20,"papers":[{"doi":"10.1080/21505594.2024.2428843","pmcid":"PMC11622590","pmid":"39620486","title":"Exploring the dynamics of gut microbiota, antibiotic resistance, and chemotherapy impact in acute leukemia patients: A comprehensive metagenomic analysis."}],"sample_intervention_arms":{},"sex":{"female":8,"male":12},"title":"The gut microbiomes and resistomes of acute leukemia patients","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1050658","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1050658_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1050658.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1050658.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1050658.csv.gz"}},{"accession":"PRJNA1283527","age_categories":{"adult":18},"countries":{"US":18},"first_public_year":"2025","gbp_per_sample_median":2.63,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":18},"intervention_design":"single_arm_before_after","intervention_detail":"Radiation + nivolumab + IDO1 inhibitor BMS-986205 (+/- TMZ)","interventions":["drug_therapy"],"n_samples":18,"papers":[{"doi":"10.1158/1078-0432.ccr-26-1124","pmcid":"PMC13473868","pmid":"42189896","title":"Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205."}],"sample_intervention_arms":{},"sex":{},"title":"Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1283527","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1283527_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1283527.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1283527.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1283527.csv.gz"}},{"accession":"PRJNA520777","age_categories":{"adult":10,"elderly":5},"countries":{},"first_public_year":"2020","gbp_per_sample_median":0.24,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"observational_with_procedure","intervention_detail":"Heart valvular replacement surgery; warfarin therapy dosing comparison (low vs high vs control responders)","interventions":["drug_therapy"],"n_samples":15,"papers":[{"doi":"10.21203/rs.3.rs-16493/v1","pmcid":null,"pmid":null,"title":"The gut microbiome affects the responses of heart valve replacement patients to the anticoagulant warfarin"}],"sample_intervention_arms":{"drug_therapy":15},"sex":{"female":12,"male":3},"title":"WGS sequencing of gut microbiome from patients receiving warfarin therapy","trial_population_condition":"cardiometabolic_other","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA520777","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA520777_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA520777.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA520777.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA520777.csv.gz"}},{"accession":"PRJEB41463","age_categories":{"child":14},"countries":{"CA":14},"first_public_year":"2020","gbp_per_sample_median":0.38,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":14},"intervention_design":"observational_with_procedure","intervention_detail":"Pegaspargase (pegylated asparaginase) chemotherapy in pediatric ALL","interventions":["drug_therapy"],"n_samples":14,"papers":[{"doi":"10.3389/fcimb.2022.924707","pmcid":"PMC9363618","pmid":"35967843","title":"Antibiotic and antifungal use in pediatric leukemia and lymphoma patients are associated with increasing opportunistic pathogens and decreasing bacteria responsible for activities that enhance colonic"},{"doi":"10.3389/fcimb.2023.1102501","pmcid":"PMC9998685","pmid":"36909730","title":"The gastrointestinal antibiotic resistome in pediatric leukemia and lymphoma patients."},{"doi":"10.1128/spectrum.00665-23","pmcid":"PMC10269646","pmid":"37191543","title":"Exploring Molecular Interactions between Human Milk Hormone Insulin and Bifidobacteria."}],"sample_intervention_arms":{},"sex":{},"title":"Examining the gut microbial community and genes in children with acute lymphoblastic leukemia that experience different levels of change in serum asparaginase activity during pegaspargase treatment","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB41463","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB41463_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB41463.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB41463.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB41463.csv.gz"}},{"accession":"PRJNA1332501","age_categories":{"unknown":12},"countries":{"CN":12},"first_public_year":"2026","gbp_per_sample_median":0.06,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"observational_with_procedure","intervention_detail":"Vedolizumab treatment in CD; FMT from donors into pseudo-germ-free mice","interventions":["drug_therapy"],"n_samples":12,"papers":[{"doi":"10.1093/ismejo/wrag028","pmcid":"PMC12998432","pmid":"41697021","title":"Gut microbial production of lithocholic acid reprograms pro-resolutive macrophages to enhance vedolizumab responsiveness via the TGR5/FXR-NF-κB axis."}],"sample_intervention_arms":{},"sex":{},"title":"Gut microbiota Raw sequence reads","trial_population_condition":"crohns_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1332501","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1332501_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1332501.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1332501.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1332501.csv.gz"}},{"accession":"PRJNA831236","age_categories":{"adult":12},"countries":{"FR":12},"first_public_year":"2022","gbp_per_sample_median":0.02,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"autoimmune_inflammatory":10,"crohns_disease":2},"intervention_design":"non_randomized_controlled","intervention_detail":"Low-dose IL-2 treatment; FMT from IL-2LD-treated donors to naive mice","interventions":["drug_therapy"],"n_samples":12,"papers":[{"doi":"10.1172/jci.insight.159406","pmcid":"PMC9536277","pmid":"35917175","title":"Low-dose IL-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation."}],"sample_intervention_arms":{"drug_therapy":6,"no_intervention":6},"sex":{},"title":"Low-dose interleukin-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation.","trial_population_condition":"autoimmune_inflammatory","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA831236","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA831236_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA831236.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA831236.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA831236.csv.gz"}},{"accession":"PRJNA313232","age_categories":{"unknown":10},"countries":{"CN":7,"DK":2,"ES":1},"first_public_year":"2016","gbp_per_sample_median":0.08,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"observational_with_procedure","intervention_detail":"Acarbose treatment in mice (diabetes drug, starch digestion inhibitor)","interventions":["drug_therapy"],"n_samples":10,"papers":[{"doi":"10.1186/s40168-016-0181-2","pmcid":"PMC4936053","pmid":"27388460","title":"Genomic characterization of the uncultured Bacteroidales family S24-7 inhabiting the guts of homeothermic animals."},{"doi":"10.1128/msphere.00851-21","pmcid":"PMC8636109","pmid":"34851167","title":"Muribaculaceae Genomes Assembled from Metagenomes Suggest Genetic Drivers of Differential Response to Acarbose Treatment in Mice."}],"sample_intervention_arms":{},"sex":{},"title":"Bacteroidales group S24-7 population genome recovery","trial_population_condition":"type2_diabetes","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA313232","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA313232_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA313232.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA313232.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA313232.csv.gz"}},{"accession":"PRJNA1300398","age_categories":{"adult":7,"elderly":2},"countries":{"SE":9},"first_public_year":"2026","gbp_per_sample_median":9.45,"has_cases_and_healthy_controls":true,"has_treated_and_control_arms":false,"health_conditions":{"healthy_control":4,"other_infection":5},"intervention_design":"single_arm_before_after","intervention_detail":"Dolutegravir (antiretroviral) treatment in people living with HIV","interventions":["drug_therapy"],"n_samples":9,"papers":[],"sample_intervention_arms":{},"sex":{"female":4,"male":3},"title":"Impact of dolutegravir on the gut microbiome and metabolic pathways in PLWH","trial_population_condition":"transplant_or_immunocompromised","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1300398","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1300398_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1300398.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1300398.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1300398.csv.gz"}},{"accession":"PRJNA551032","age_categories":{"adult":4},"countries":{},"first_public_year":"2019","gbp_per_sample_median":6.54,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"unknown","intervention_detail":"Gout treatment comparison vs untreated patients and controls","interventions":["drug_therapy"],"n_samples":4,"papers":[{"doi":"10.1016/j.jgg.2021.06.009","pmcid":null,"pmid":"34509383","title":"Characteristic dysbiosis in gout and the impact of a uric acid-lowering treatment, febuxostat on the gut microbiota."}],"sample_intervention_arms":{},"sex":{},"title":"humman gut microbiota metagenome sequensing Raw sequence reads","trial_population_condition":"other_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA551032","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA551032_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA551032.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA551032.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA551032.csv.gz"}},{"accession":"PRJNA1333823","age_categories":{"adult":1},"countries":{"CN":1},"first_public_year":"2025","gbp_per_sample_median":0.05,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"gi_infection_or_diarrhoea":1},"intervention_design":"none","intervention_detail":"","interventions":[],"n_samples":1,"papers":[],"sample_intervention_arms":{"drug_therapy":1},"sex":{"male":1},"title":"Metagenomic diagnosis of a human transverse colon biopsy sample","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1333823","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1333823_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1333823.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1333823.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1333823.csv.gz"}},{"accession":"PRJNA1517838","age_categories":{"adult":1},"countries":{"KR":1},"first_public_year":"2026","gbp_per_sample_median":12.91,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"obesity":1},"intervention_design":"single_arm_before_after","intervention_detail":"Short course metformin treatment in obese adults, serial stool sampling","interventions":["drug_therapy"],"n_samples":1,"papers":[],"sample_intervention_arms":{"no_intervention":1},"sex":{},"title":"ObMET Stool Raw sequence reads","trial_population_condition":"obesity","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1517838","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1517838_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1517838.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1517838.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1517838.csv.gz"}},{"accession":"PRJNA593062","age_categories":{"unknown":1},"countries":{"US":1},"first_public_year":"2020","gbp_per_sample_median":12.43,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"observational_with_procedure","intervention_detail":"Ex vivo drug metabolism screen on personalized fecal microbial communities; no in vivo drug given to subjects","interventions":["drug_therapy"],"n_samples":1,"papers":[{"doi":"10.1016/j.cell.2020.05.001","pmcid":"PMC8591631","pmid":"32526207","title":"Personalized Mapping of Drug Metabolism by the Human Gut Microbiome."},{"doi":"10.7554/elife.82401","pmcid":"PMC10289814","pmid":"37306300","title":"SIMMER employs similarity algorithms to accurately identify human gut microbiome species and enzymes capable of known chemical transformations."}],"sample_intervention_arms":{},"sex":{},"title":"Sequencing data for \"Mapping drug metabolism by the human gut microbiome using personalized microbial communities\"","trial_population_condition":"healthy_control","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA593062","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA593062_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA593062.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA593062.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA593062.csv.gz"}}],"release":"R2026.25"}